Petition to Include ASCORBYL PALMITATE at 7 CFR 205.605

Item A

This petition seeks inclusion of ASCORBYL PALMITATE on the National List at §205.605(b) as a synthetic non-agricultural substance allowed in or on processed infant formula products labeled as “organic” or “made with organic (specified ingredients).”

Item B

1. The substance’s chemical or common name.

Ascorbyl palmitate is an ester of ascorbic acid (a substance providing Vitamin C) and palmitic acid, a saturated fatty acid which comprises 25% of the fatty acids in breast milk lipid. Ascorbyl palmitate is known as "vitamin C ester," which should not be confused with “Ester-C®,” a branded Vitamin C supplement comprised of calcium ascorbate.

Other chemical names for ascorbyl palmitate are Vitamin C palmitate; L-ascorbyl palmitate; 2,3-didehydro-L-threo-hexono-1,4-lactone-6-palmitate; 6-palmitoyl-3-keto-L-gulofuranolactone; and L-ascorbic acid 6-hexadecanoate.

2a. The petitioner’s name, address and telephone number and other contact information.

International Formula Council
1100 Johnson Ferry Road NE, Suite 300
Atlanta, GA 30342
Contact: Mardi Mountford, Executive Vice President
Phone: (678) 303-3027
Email: mmountford@kellencompany.com

2b. Sources of the petitioned substance.

The number of manufacturers of ascorbyl palmitate is very large. The information available for ascorbyl palmitate on the Hazardous Substances Data Bank (see Appendix A) lists the names of 20 suppliers from around the world (pages 30-32).

The supplier of the ascorbyl palmitate used in infant formulas is DSM Nutritional Products.
Contact information for DSM Nutritional Products:

**Postal address**
DSM Nutritional Products GmbH
Postfach 1145
D-79629 Grenzach-Wyhlen, Germany
http://www.dsm-grenzach.de

**Street address**
DSM Nutritional Products GmbH
Emil-Barell-Str. 3
D-79639 Grenzach-Wyhlen, Germany
Tel.: +49 7624 9090
3. The intended or current use of the substance.

Ascorbic acid, which is water-soluble, has antioxidant activity, both in the body and in foods. Ascorbyl palmitate is fat-soluble, so it provides a means for providing the antioxidant activity of ascorbic acid in edible oils blends such as those used in infant formulas.

Note that ingestion of ascorbyl palmitate does not result in any significant incorporation into the body because ascorbyl palmitate is hydrolyzed to palmitate and ascorbic acid in the human digestive tract before it is absorbed. The ascorbic acid released by the hydrolysis of ascorbyl palmitate appears to be as bioavailable as ascorbic acid itself.

This petition requests the addition of ascorbyl palmitate solely for use in infant formula labeled as “organic.” Ascorbyl palmitate is used in many conventional food products as an antioxidant. The standard of identity for margarine (21 CFR 166.110) permits use of ascorbyl palmitate. FDA regulations allow use of ascorbyl palmitate in foods for human consumption (21 CFR 182.3149) and in animal drugs, feeds, and related products (21 CFR 582.3149) in accordance with good manufacturing (or feeding) practice. Ascorbyl palmitate in foods prevents rancidity and the browning of cut apples.

4. A list of the handling activities for which the substance will be used.

This petition seeks allowance of ascorbyl palmitate as an antioxidant ingredient in infant formula products. Infant formulas commonly contain a variety of polyunsaturated chain fatty acids (PUFA) as part of the lipid component of the overall nutrient system. Examples of PUFA include linoleic acid, alpha-linolenic acid, arachidonic acid (ARA), docosahexaenoic acid (DHA), and others. The Infant Formula Act and FDA regulations require a minimum amount of linoleic acid in order to provide essential fatty acid. ARA and DHA have been shown to provide beneficial effects in preterm infants such as enhanced brain and vision development.

PUFA tend to be more sensitive to oxidation than many other ingredients commonly found in nutritional formulas. Due to their chemical structure, exposure of PUFA to heat and atmospheric levels of oxygen can cause a series of chemical reactions resulting in free radical formation. These free radicals can continue to break down PUFA in an auto-oxidative process. The result is the development of undesirable off-flavors and odors and the eventual degradation of the beneficial polyunsaturated fatty acids. PUFA are especially susceptible to oxidation during high-heat processing, spray drying processing, or even during relatively short storage periods after the formula has been sealed and packaged. Oxidative stability has become especially challenging with infant formulas that contain ARA and DHA, two fatty acids found in human milk that are important for visual and cognitive development.

One method of controlling the undesirable oxidation of PUFA in powdered infant formulas is the addition of safe antioxidants soluble in edible oils, such as ascorbyl palmitate, beta-carotene, mixed tocopherols, and others.
5. **Detailed description of the manufacturing process.**

Ascorbyl palmitate is prepared by condensing palmitoyl chloride and ascorbic acid in the presence of a dehydrochlorinating agent such as pyridine. It is also formed by the reaction of L-ascorbic acid and palmitic acid, which can be catalyzed by lipase enzyme.

6. **Summary of any available previous reviews of the petitioned substance.**

The [Hazardous Substances Data Bank](http://toxnet.nlm.nih.gov) information on ascorbyl palmitate available at the National Library of Medicine website is attached as Appendix A.

The Select Committee on GRAS Substances (SCOGS) was established by the Life Sciences Research Office (LSRO) under contract with the Food and Drug Administration to evaluate over 370 substances used as food additives. The Select Committee of GRAS Substances (SCOGS) was a group of qualified scientists assigned to provide an independent evaluation of the safety of food additives, including ascorbyl palmitate. In their report published in 1979, their judgment was: “There is no evidence in the available information on ascorbyl palmitate that demonstrates, or suggests reasonable grounds to suspect, a hazard to the public when they are used at levels that are now current or might reasonably be expected in the future.”

7. **Information regarding the regulatory status of ascorbyl palmitate.**

FDA regulations allow use of ascorbyl palmitate as an antioxidant in foods for human consumption (21 CFR 182.3149) and in animal drugs, feeds, and related products (21 CFR 582.3149) in accordance with good manufacturing (or feeding) practice. The standard of identity for margarine (21 CFR 166.110) permits use of ascorbyl palmitate limited to 0.02% percent by weight of the finished food. FSIS also permits ascorbyl palmitate in margarine at up to 0.02% to retard rancidity (9 CFR 424.21).

The FDA is the official U.S. government representative to the Codex Alimentarius Commission of the Joint FAO/WHO Food Standards Programme. The Codex Alimentarius Commission Standard for Infant Formula (CODEX STAN 72-1981) has listed L-ascorbyl palmitate (and mixed tocopherols concentrate) as permissible antioxidants in infant formula for over thirty years, at a maximum level of 1 mg/100 mL of prepared ready-to-feed infant formula, singly or in combination with mixed tocopherol concentrate.

---

Moreover, the Codex Alimentarius Commission created Advisory Lists of Mineral Salts and Vitamin Compounds for Use in Foods for Infants and Children, CAC/GL 10-1979. For Vitamin C, CAC/GL 10-1979 lists four (4) vitamin forms: ascorbic acid, sodium ascorbate, calcium ascorbate, and ascorbyl-6-palmitate. It is no accident that the list of vitamins prepared for the Processing, Handling, and Labeling Committee of the National Organic Standards Board in 1994 or 1995, that was included in the Nutrient Vitamins TAP Report (at page 7), listed these same four vitamin forms for Vitamin C. One of the “vitamins” approved by the NOSB in October/November 1995 was “Vitamin C.” “Vitamin C” is not a substance, but a vitamin activity provided by a substance, such as the four vitamin forms enumerated in CAC/GL 10-1979 and in the listing included in the “Nutrient Vitamins” TAP Report.

According to the EPA’s FIFRA Requirements, residues of ascorbyl palmitate are exempted from the requirement of a tolerance when used in accordance with good agricultural practice as inert (or occasionally active) ingredients in pesticide formulations applied to growing crops or to raw agricultural commodities after harvest (40 CFR 180.910) and in pesticide formulations applied to animals (40 CFR 180.930).

8a. The Chemical Abstract Service (CAS) No. of ascorbyl palmitate is 137-66-6. The INS number (“E number”) of ascorbyl palmitate is 304.

8b. Labels of products that contains the petitioned substance

See Appendix B

9. The substance’s physical properties and chemical mode of action

Ascorbyl palmitate is a white or yellowish-white solid with a soapy taste and a citrus-like odor. It is very slightly soluble in water but freely soluble in alcohol, animal oil, and vegetable oil. It melts at 107° to 117°C (around 234°F).

Ascorbyl palmitate prevents oxidative rancidity development by quenching singlet oxygen. The ascorbic acid part of the molecule donates hydrogen (a reducing agent). This phenomenon is also called “oxygen scavenging.”

(a) Chemical interactions with other substances, especially substances used in organic production

As a fat-soluble source of ascorbic acid, ascorbyl palmitate acts synergistically with tocopherols to protect fats and oils from rancidity.

Ascorbyl palmitate may protect against certain drugs. Male MEI mice in which hepatotoxicity had been induced by the feeding of 600 mg/kg acetaminophen had covalent binding of acetaminophen metabolites to hepatic proteins, a depletion of hepatic nonprotein sulphydryl
groups after 2 hours, and a dramatic increase in plasma alanine aminotransferase activity after 24 hours. The coadministration of acetaminophen and ascorbyl palmitate reduced this binding within 2 and 4 hours (to 31% and 22%, respectively), reduced the depletion in nonprotein sulfhydryl groups and aminotransferase activity, and completely prevented the 35% mortality observed at 24 hours after acetaminophen treatment alone. Ascorbyl palmitate appeared to prevent hepatic damage by removing the reactive acetaminophen metabolites and by having a sparing action on reduced hepatic glutathione.

(b) toxicity and environmental persistence

For at least thirty years, the Codex Alimentarius Commission Standard for Infant Formula (CODEX STAN 72-1981) has listed L-ascorbyl palmitate (and mixed tocopherols concentrate) as permissible antioxidants in infant formula, at a level of up to 1 mg/100 mL in prepared ready-to-feed product.

Rats (10 per group) were given 2% and 5% ascorbyl palmitate (AP) in feed for 9 months. Significant growth retardation occurred in rats given 5% AP, and 2 of 10 had bladder stones and hyperplasia of the bladder epithelium. One rat of the high dose group had lesions of nephritis. Slight growth retardation occurred in rats fed the 2% AP diet, but no other signs of toxicity were observed. Female mice fed AP for 63 days had no signs of toxicity during a tumor inhibition study at doses up to 3000 mg/kg/day.

High doses of ascorbic acid increase oxalic acid production and excretion. Rats fed 125 mg AP per kg per day for 728 days (0.25% of diet) had no harmful effects. This intake was the equivalent of 53 mg/kg of ascorbic acid per day. In the same study, however, a different group of rats had body weight decreases at dietary doses of 2500 mg/kg/day and above. The highest dose that did not cause a toxicological effect was 1000 mg/kg/day. Additionally, oxalate stones were observed in the urinary bladders of two of the eight rats in the second group when a dose of 2500 mg/kg/day was administered.

Ascorbyl palmitate has antitumor activity. AP was topically applied at small doses inhibited 12-O-tetradecanoylphorbol-13-acetate-induced (TPA-induced) ornithine decarboxylase activity, tumor production, and DNA synthesis in mouse epithelial cells. A dose of 4 µmol of AP inhibited by 60-70% after one topical application of 2 nmol TPA. When 5 nmol TPA was administered with 5 pmol AP twice weekly to previously initiated mice, 91% of tumors were inhibited per mouse.

Ascorbyl palmitate is nonmutagenic and actually behaves as a membrane-active antimutagen.

(c) environmental impacts from its use and/or manufacture

Ascorbyl palmitate's production and use as an antioxidant and as a chemical preservative food additive may result in its release to the environment through various waste streams. If released to air, an estimated vapor pressure of 2.09X10^{-15} mm Hg at 25 deg C indicates ascorbyl palmitate
will exist solely in the particulate phase in the atmosphere. Particulate-phase ascorbyl palmitate will be removed from the atmosphere by wet or dry deposition. Ascorbyl palmitate does not contain chromophores that absorb at wavelengths >290 nm, and therefore is not expected to be susceptible to direct photolysis by sunlight. If released to soil, ascorbyl palmitate is expected to have moderate mobility based upon an estimated Koc of 450. Volatilization from moist soil surfaces is not expected to be an important fate process based upon an estimated Henry's Law constant of 1.4X10^-7 atm-cu m/mole. Biodegradation data were not available.

If released into water, ascorbyl palmitate is expected to adsorb to suspended solids and sediment based upon the estimated Koc. Volatilization from water surfaces is not expected to be an important fate process based upon the compound's estimated Henry's Law constant. An estimated bioconcentration factor (BCF) of 180 suggests the potential for bioconcentration in aquatic organisms is high, provided the compound is not metabolized by the organism. An estimated base-catalyzed second-order hydrolysis rate constant of 2.85X10^-2 L/mole-sec corresponds to half-lives of 7.7 years and 280 days at pH values of 7 and 8, respectively.

Occupational exposure to ascorbyl palmitate may occur through inhalation and dermal contact with this compound at workplaces where ascorbyl palmitate is produced or used. Use data indicate that the general population may be exposed to ascorbyl palmitate via ingestion of food and via use of pharmaceutical products and antioxidants containing ascorbyl palmitate.

(d) effects on human health

The 1979 opinion on ascorbyl palmitate of the Select Committee on GRAS Substances (SCOGS) of the Life Sciences Research Office (LSRO)², which reviewed the safety of over 370 food additives under contract with the Food and Drug Administration and affirmed the GRAS status of ascorbyl palmitate, was that there is no evidence in the available information on ascorbyl palmitate that demonstrates, or suggests reasonable grounds to suspect, a hazard to the public when used at levels that are now current or might reasonably be expected in the future.

Ascorbyl palmitate is used widely in cosmetics. Ascorbyl palmitate at concentrations of 1%, 3%, and 5% in petrolatum (0.025 g) was applied under occlusive conditions to the scapular back of human subjects three times per week for 3 consecutive weeks, and once in the 4th week (10 applications). Ascorbyl palmitate at 1-5% was not sensitizing.

(e) effects on soil organisms, crops, or livestock

Oral supplementation of ascorbyl palmitate equivalent to 20 mg ascorbic acid per kg body weight on pulmonary and systemic antioxidant status was studied in six healthy ponies. Two

weeks supplementation with ascorbyl palmitate significantly increased mean plasma ascorbic acid concentrations compared to control (29 ±5 and 18 ±7 µmol/L; p < 0.05). The concentration of ascorbic acid in bronchoalveolar lavage fluid increased in five out of six ponies following supplementation with ascorbyl palmitate compared with control (30 ± 10 and 18 ±8 µmol/L; p < 0.01). AP did not alter the concentration of glutathione, uric acid or alpha-tocopherol in plasma or bronchoalveolar lavage fluid. In conclusion, the concentration of lung lining fluid ascorbic acid is increased following ascorbyl palmitate supplementation (20 mg/kg body weight) in an ascorbate-synthesizing species.

10a. Safety information about the substance including a Material Safety Data Sheet (MSDS).
An MSDS for ascorbyl palmitate is attached as Appendix C.

An NIEHS substance report may not exist. Appendix A provides the Hazardous Substance Data Bank information on ascorbyl palmitate.

11. Research information about ascorbyl palmitate.
The opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies of the European Food Safety Authority on a request from the European Commission related to the Tolerable Upper Intake Level of Vitamin C in the form of L-ascorbic acid, its calcium, potassium and sodium salts, and L-ascorbyl-6-palmitate is attached as Appendix D. This opinion indicates that safe ascorbic acid intakes can far exceed the amount of ascorbic acid added as ascorbyl palmitate in infant formulas.

Reviews and bibliographies presenting contrasting positions to those presented herein have not been located.

Infant formulas are, by FDA regulation, high-fat products providing up to 50% of food energy from lipid. It is important to protect the fats and oils used in infant formulas from oxidation. Fat oxidation is a real danger in powdered infant formula especially, since these products are dried by high temperature spray-drying in an oxygen-containing atmosphere.

The National List at §205.605(b) currently permits addition to foods labeled as “organic” of the antioxidant tocopherols “derived from vegetable oil when rosemary extracts are not a suitable alternative.” For infant formula, rosemary extracts are not a suitable option. Rosemary and
rosemary extracts and oils may be GRAS (21 CFR 182.10 and 21 CFR 182.20) for use as spices and flavorings in foods for the general population, but have not been tested and accepted for use in infant formula, the food that constitutes the sole item of diet of infants for an extended period of time. Rosemary oil and extracts contains a range of compounds with various pharmacological activities. An antioxidant found in rosemary (Rosmarinus officinalis) and common sage (Salvia officinalis) is carnosic acid, a benzenediol diterpene. Although carnosic acid is used as a preservative or antioxidant in food and nonfood products (e.g. toothpaste, mouthwash, chewing gum, and skin care products), carnosic acid has medicinal properties, as well as being a potent antioxidant. Because of possible side effects (abortifacient, other toxic side effects; unknown effects in infants) of the components of rosemary oil and rosemary extracts, it is not prudent to use these substances in foods for young infants.

Tocopherols derived from vegetable oil are in fact currently used in infant formulas as antioxidants to protect the edible oils from oxidation and rancidity, but their functionality is limited. One reason that ascorbyl palmitate is added to infant formulas is that it works synergistically with tocopherols. A number of different and complementary antioxidant systems are required to enable the sensitive lipid component of infant formulas to survive the several processing steps of infant formula manufacture and packaging.

Ascorbyl palmitate combines the vitamin form ascorbic acid (providing Vitamin C activity) and the fatty acid palmitic acid, one of the most common fatty acids in human milk. Ascorbyl palmitate is a safe and effective antioxidant in infant formula. It is GRAS.

Lastly, one of the nutrient vitamins approved by the NOSB in October/November 1995 was “Vitamin C.” “Vitamin C” is not a substance, but a vitamin activity provided by a substance. The Codex Alimentarius Commission created Advisory Lists of Mineral Salts and Vitamin Compounds for Use in Foods for Infants and Children, CAC/GL 10-1979. For Vitamin C, CAC/GL 10-1979 lists four (4) vitamin forms: ascorbic acid, sodium ascorbate, calcium ascorbate, and ascorbyl-6-palmitate. It is no accident that the list of vitamins prepared for the Processing, Handling, and Labeling Committee of the National Organic Standards Board in 1994 or 1995 and that was included in the Nutrient Vitamins TAP Report (at page 7) listed these same four vitamin forms for Vitamin C. Consequently, sixteen years ago, the NOSB actually approved ascorbyl palmitate, at least as a source of Vitamin C activity, for use in foods labeled as “organic.”

13. Confidential Business Information Statement

This petition contains no confidential business information.
Appendices

Petition for addition to the National List of ASCORBYL PALMITATE on the National List of Substances Allowed as Ingredients in or on Processed Products Labeled as “organic” or “made with organic (specified ingredients or food group(s)).”

Appendix A – Hazardous Substance Data Bank information

Appendix B – Labels of infant formulas containing this substance

Appendix C - MSDS

Appendix D - Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies of the European Food Safety Authority (EFSA)
Human Health Effects:

**Human Toxicity Excerpts:**

/HUMAN EXPOSURE STUDIES/ One hundred nineteen subjects were enrolled in a modified Draize assay for skin sensitization potential. Of those, 106 completed the study. Ascorbyl palmitate at concentrations of 1%, 3%, and 5% in petrolatum (0.025 g) was applied under occlusive conditions to the scapular back using a Finn Chamber. The test materials were applied three times per week for 3 consecutive weeks, and once in the 4th week (10 applications). The patch sites were evaluated 48 or 72 hours after application. Twelve days after the last patch was removed, a challenge patch was applied to an untreated skin site on the scapular back. The patch was removed at 48 hours, and the site was scored at patch removal and at 96 hours.

One subject had a rash on his torso during the 3rd week of the study, but this was attributed to exclusionary medication that was not reported on the subject's personal and medical history, and was not related to the test substances. During induction, the 1% preparation caused seven 1+ reactions in a single subject. No reactions were noted for the 3% preparation, and one subject had five 1+ reactions after being treated with the 5% preparation. Under the conditions of this study, the investigators concluded that 1-5% ascorbyl palmitate was not sensitizing.


/HUMAN EXPOSURE STUDIES/ A maximization test using 15 female and 13 male subjects was performed to determine the contact sensitization potential of an eye cream containing 0.2% ascorbyl palmitate. Skin sites on the upper outer arm, volar forearm, or back of each subject were pretreated with 0.1 mL of sodium lauryl sulfate (SLS) at a concentration of 0.25% and covered with occlusive patches for 24 hours. At patch removal, 0.1 mL of the test eye cream was applied to the same site and covered with occlusive tape. This induction patch remained in place for 48 hours, after which it was removed and the test site was examined for signs of irritation. If no irritation was observed, the pretreatment-treatment procedure was repeated at the same skin site for a total of five induction exposures. If irritation was observed, the treatment patch only was applied for the duration of the study. Ten days after the last induction patch application, 0.1 mL of SLS (5.0%) was applied to an untreated skin site under an occlusive patch for 1 hour. The SLS patch was removed and replaced with a challenge patch containing the eye cream. At 48 h
and 72 hours, the skin sites were examined for sensitization. Twenty-six subjects completed the study; the remaining 2 subjects withdrew for reasons unrelated to the study. No adverse reactions or signs of dermal sensitization were observed during this study.

/ALTERNATIVE and IN VITRO TESTS/

Rapidly growing tumor cells in rodents and humans have high glutathione S-transferase (GST) activity, and GST can be involved in tumor cell drug resistance. Ascorbyl palmitate significantly inhibited human term placental and fetal liver GST activity towards its second substrate, 1-chloro-2, 4-dinitrobenzene (K=10.0 uM). The I50 (uM) for ascorbyl palmitate was 45 +/- 0.3 when tested using cultures of human fetal liver, and 6 +/- 1.5 using cultures of rat liver.

/OTHER TOXICITY INFORMATION/

Glutathione-S-transferase (GST) activity from human term placenta and human fetal liver towards 1-chloro-2,4-dinitrobenzene as the second substrate was significantly inhibited by the saturated fatty acids, stearic (SA) and palmitic (PA) acids and fatty acid esters, ascorbyl stearate (Asc-S) and ascorbyl palmitate (Asc-P). The nature of inhibition of human placental GST was competitive towards CDNB with Ki values of 3.1, 10.0, 13.5 and 18.5 uM for Asc-S, Asc-P, PA and SA, respectively. The inhibitory effect of Asc-S on human term placental GST was reversible. I50 values for Asc-S, Asc-P, SA and PA were 15, 45, 83 and 78 uM, respectively, for partially purified human fetal liver GSTs and 21, 6, 88 and 117 uM, respectively, for partially pure rat liver GSTs...

Probable Routes of Human Exposure:

NIOSH (NOES Survey 1981-1983) has statistically estimated that 3,051 workers (1,122 of these were female) were potentially exposed to ascorbyl palmitate in the US(1). Occupational exposure to ascorbyl palmitate may occur through inhalation and dermal contact with this compound at workplaces where ascorbyl palmitate is produced or used. Use data indicate that the general population may be exposed to ascorbyl palmitate via ingestion of food and via use of pharmaceutical products and antioxidants containing ascorbyl palmitate. (SRC)
Emergency Medical Treatment:

Emergency Medical Treatment:
EMT Copyright Disclaimer:

Portions of the POISINDEX(R) and MEDITEXT(R) database have been provided here for general reference. THE COMPLETE POISINDEX(R) DATABASE OR MEDITEXT(R) DATABASE SHOULD BE CONSULTED FOR ASSISTANCE IN THE DIAGNOSIS OR TREATMENT OF SPECIFIC CASES. The use of the POISINDEX(R) and MEDITEXT(R) databases is at your sole risk. The POISINDEX(R) and MEDITEXT(R) databases are provided "AS IS" and "as available" for use, without warranties of any kind, either expressed or implied. Micromedex makes no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the POISINDEX(R) and MEDITEXT(R) databases. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Micromedex does not assume any responsibility or risk for your use of the POISINDEX(R) or MEDITEXT(R) databases. Copyright 1974-2011 Thomson MICROMEDEX. All Rights Reserved. Any duplication, replication, "downloading," sale, redistribution or other use for commercial purposes is a violation of Micromedex’ rights and is strictly prohibited.

The following Overview, *** VITAMINS-MULTIPLE ***, is relevant for this HSDB record chemical.

Life Support:
- This overview assumes that basic life support measures have been instituted.

Clinical Effects:

0.2.1 SUMMARY OF EXPOSURE
  0.2.1.1 ACUTE EXPOSURE
  A) Toxicity following acute overdoses with multiple vitamin preparations is unlikely unless a massive amount has been ingested.
  B) The expected signs and symptoms of toxicity would be that of the individual vitamin preparations, especially A and D and iron (see appropriate individual Managements). Gastrointestinal irritation and diarrhea are the most frequently reported findings after ingestion.
  C) Most of the water soluble vitamins (folic acid, thiamine (B1), riboflavin (B2), cyanocobalamin (B12), biotin, pantothenic acid) produce no acute toxic symptoms. Chronic ingestion of megadoses may be a more serious problem. An acute intravenous overdose of vitamin C has resulted in renal failure.

0.2.4 HEENT
  0.2.4.1 ACUTE EXPOSURE
  A) Chronic administration of large doses of niacin has been associated with cystoid maculopathy.

0.2.7 NEUROLOGIC
0.2.7.1 ACUTE EXPOSURE
A) Pure sensory axonal neuropathy, with symptoms of paresthesias, numbness, pain, and weakness may occur after chronic ingestion of pyridoxine.

0.2.8 GASTROINTESTINAL
0.2.8.1 ACUTE EXPOSURE
A) Nausea, vomiting, abdominal pain, and diarrhea are common, especially following ingestion of multiple vitamins with iron (see iron management).
B) Vitamin C tablets may become lodged in the esophagus when swallowed with minimal fluids.

0.2.9 HEPATIC
0.2.9.1 ACUTE EXPOSURE
A) Chronic high-dose niacin use has been associated with both cholestatic and hepatocellular liver injury, particularly with sustained-release preparations.

0.2.10 GENITOURINARY
0.2.10.1 ACUTE EXPOSURE
A) Large intravenous doses of vitamin C may precipitate acute renal failure. Riboflavin may cause a bright yellow discoloration of urine.

0.2.13 HEMATOLOGIC
0.2.13.1 ACUTE EXPOSURE
A) Vitamin C supplementation may cause hemolytic anemia in premature neonates.

0.2.14 DERMATOLOGIC
0.2.14.1 ACUTE EXPOSURE
A) Niacin (vitamin B3) may cause intense cutaneous flushing lasting up to 2 to 3 hours with no other apparent toxicity. Nicotinamide lacks these effects. Topical vitamin E has rarely caused contact dermatitis and erythema multiforme.

0.2.19 IMMUNOLOGIC
0.2.19.1 ACUTE EXPOSURE
A) Anaphylactoid reactions occur rarely after intravenous thiamine.

0.2.20 REPRODUCTIVE HAZARDS
A) There is a well-established association between some vitamin A congeners and a teratogenic outcome in infants whose mothers were exposed during pregnancy.

Laboratory:
A) Plasma levels of the individual vitamins are not clinically useful. However, if iron toxicity is suspected, a serum iron should be determined (see IRON Management).
B) No specific lab work (CBC, electrolytes, urinalysis) is needed unless otherwise indicated.

Treatment Overview:
0.4.2 ORAL EXPOSURE
A) Gastrointestinal decontamination is not necessary in most cases. It should be considered if a potentially toxic dose of vitamin A or D has been ingested. Acute ingestion of 300,000 units of vitamin A by children or 1 million units by adults has caused toxicity (see vitamin A management for details).
B) ACTIVATED CHARCOAL: Administer charcoal as a slurry (240 mL water/30 g charcoal). Usual dose: 25 to 100 g in adults/adolescents, 25 to 50 g in children (1 to 12 years), and 1 g/kg in infants less than 1 year old.

C) Dilution with fluids may be indicated following accidental ingestion of vitamin C tablets.

D) Toxicity is unlikely following acute ingestion of multiple vitamin preparations without iron. Iron toxicity may occur following ingestion of those preparations which contain iron salts (see Multivitamins - Iron management).

E) Vitamin A toxicity may occur following massive overdose (see Vitamin A management).

F) Vitamin D toxicity may occur following massive overdose (see Vitamin D management).

Range of Toxicity:

A) Toxicity following acute overdoses of multiple vitamin preparations is unlikely unless the preparation contains significant amounts of iron, vitamin A, or vitamin D.

UNITED STATES

RECOMMENDED DAILY ALLOWANCES OF VITAMINS AND MINERALS

<table>
<thead>
<tr>
<th>Units</th>
<th>Adults &amp; Pregnant or Lactating greater than 4 years age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin A</td>
<td>International 5000 Unit</td>
</tr>
<tr>
<td></td>
<td>Vitamin D International 400 Unit</td>
</tr>
<tr>
<td></td>
<td>Vitamin E International 30 Unit</td>
</tr>
<tr>
<td>Vitamin C</td>
<td>mg 60</td>
</tr>
<tr>
<td>Folic Acid</td>
<td>mg 0.4</td>
</tr>
<tr>
<td>Thiamine B1</td>
<td>mg 1.5</td>
</tr>
<tr>
<td>Riboflavin B2</td>
<td>mg 1.7</td>
</tr>
<tr>
<td>Niacin</td>
<td>mg 20</td>
</tr>
<tr>
<td>Vitamin B6</td>
<td>mg 2</td>
</tr>
<tr>
<td>Vitamin B12</td>
<td>mcg 6</td>
</tr>
<tr>
<td>Biotin</td>
<td>mg 0.3</td>
</tr>
<tr>
<td>Pantothenic Acid</td>
<td>mg 10</td>
</tr>
<tr>
<td>Calcium</td>
<td>g 1</td>
</tr>
<tr>
<td>Phosphorus</td>
<td>g 1</td>
</tr>
<tr>
<td>Iodine</td>
<td>mcg 150</td>
</tr>
<tr>
<td>Iron</td>
<td>mg 18</td>
</tr>
<tr>
<td>Magnesium</td>
<td>mg 400</td>
</tr>
<tr>
<td>Copper</td>
<td>mg 2</td>
</tr>
<tr>
<td>Zinc</td>
<td>mg 15</td>
</tr>
</tbody>
</table>

UNITED STATES

RECOMMENDED DAILY ALLOWANCES OF VITAMINS AND MINERALS

<table>
<thead>
<tr>
<th>Units</th>
<th>Infants (0 to 12 mo) less than 4 years</th>
<th>Adults and Children greater than 4 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin C</td>
<td>mg 60</td>
<td>mg 60</td>
</tr>
<tr>
<td>Folic Acid</td>
<td>mg 0.4</td>
<td>mg 0.8</td>
</tr>
<tr>
<td>Thiamine B1</td>
<td>mg 1.5</td>
<td>mg 1.7</td>
</tr>
<tr>
<td>Riboflavin B2</td>
<td>mg 1.7</td>
<td></td>
</tr>
<tr>
<td>Niacin</td>
<td>mg 20</td>
<td>mg 20</td>
</tr>
<tr>
<td>Vitamin B6</td>
<td>mg 2</td>
<td>mg 2</td>
</tr>
<tr>
<td>Vitamin B12</td>
<td>mcg 6</td>
<td>mcg 8</td>
</tr>
<tr>
<td>Biotin</td>
<td>mg 0.3</td>
<td>mg 0.3</td>
</tr>
<tr>
<td>Pantothenic Acid</td>
<td>mg 10</td>
<td></td>
</tr>
<tr>
<td>Calcium</td>
<td>g 1</td>
<td>g 1.3</td>
</tr>
<tr>
<td>Phosphorus</td>
<td>g 1</td>
<td>g 1.3</td>
</tr>
<tr>
<td>Iodine</td>
<td>mcg 150</td>
<td>mcg 150</td>
</tr>
<tr>
<td>Iron</td>
<td>mg 18</td>
<td>mg 18</td>
</tr>
<tr>
<td>Magnesium</td>
<td>mg 400</td>
<td>mg 450</td>
</tr>
<tr>
<td>Copper</td>
<td>mg 2</td>
<td>mg 2</td>
</tr>
<tr>
<td>Zinc</td>
<td>mg 15</td>
<td>mg 15</td>
</tr>
</tbody>
</table>
### Antidote and Emergency Treatment:

**/SRP:/ Immediate first aid:** Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. **/Poisons A and B/**

**/SRP:/ Basic treatment:** Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... Monitor for shock and treat if necessary ... Anticipate seizures and treat if necessary ... For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient

<table>
<thead>
<tr>
<th>Substance</th>
<th>Dietary Reference Intakes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vitamin A</strong></td>
<td>Internat-</td>
</tr>
<tr>
<td></td>
<td>ional Unit</td>
</tr>
<tr>
<td></td>
<td>1500</td>
</tr>
<tr>
<td></td>
<td>2500</td>
</tr>
<tr>
<td></td>
<td>5000</td>
</tr>
<tr>
<td><strong>Vitamin D</strong></td>
<td>Internat-</td>
</tr>
<tr>
<td></td>
<td>ional Unit</td>
</tr>
<tr>
<td></td>
<td>400</td>
</tr>
<tr>
<td></td>
<td>400</td>
</tr>
<tr>
<td></td>
<td>400</td>
</tr>
<tr>
<td><strong>Vitamin E</strong></td>
<td>Internat-</td>
</tr>
<tr>
<td></td>
<td>ional Unit</td>
</tr>
<tr>
<td></td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>30</td>
</tr>
<tr>
<td><strong>Vitamin C</strong></td>
<td>mg</td>
</tr>
<tr>
<td></td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>60</td>
</tr>
<tr>
<td><strong>Folic Acid</strong></td>
<td>mg</td>
</tr>
<tr>
<td></td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td>0.2</td>
</tr>
<tr>
<td></td>
<td>0.4</td>
</tr>
<tr>
<td><strong>Thiamine</strong></td>
<td>mg</td>
</tr>
<tr>
<td></td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>0.7</td>
</tr>
<tr>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td><strong>Riboflavin</strong></td>
<td>mg</td>
</tr>
<tr>
<td></td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td>0.8</td>
</tr>
<tr>
<td></td>
<td>1.7</td>
</tr>
<tr>
<td><strong>Niacin</strong></td>
<td>mg</td>
</tr>
<tr>
<td></td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>20</td>
</tr>
<tr>
<td><strong>Vitamin B6</strong></td>
<td>mg</td>
</tr>
<tr>
<td></td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>0.7</td>
</tr>
<tr>
<td></td>
<td>2</td>
</tr>
<tr>
<td><strong>Vitamin B12</strong></td>
<td>mcg</td>
</tr>
<tr>
<td></td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>3</td>
</tr>
<tr>
<td><strong>Biotin</strong></td>
<td>mg</td>
</tr>
<tr>
<td></td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>0.15</td>
</tr>
<tr>
<td></td>
<td>0.3</td>
</tr>
<tr>
<td><strong>Pantothe-</strong></td>
<td>mg</td>
</tr>
<tr>
<td><strong>nic Acid</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>10</td>
</tr>
<tr>
<td><strong>Calcium</strong></td>
<td>g</td>
</tr>
<tr>
<td></td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td>0.8</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td><strong>Phosphorus</strong></td>
<td>g</td>
</tr>
<tr>
<td></td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>0.8</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td><strong>Iodine</strong></td>
<td>mcg</td>
</tr>
<tr>
<td></td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>150</td>
</tr>
<tr>
<td><strong>Iron</strong></td>
<td>mg</td>
</tr>
<tr>
<td></td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>18</td>
</tr>
<tr>
<td><strong>Magnesium</strong></td>
<td>mg</td>
</tr>
<tr>
<td></td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>400</td>
</tr>
<tr>
<td><strong>Copper</strong></td>
<td>mg</td>
</tr>
<tr>
<td></td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>2</td>
</tr>
<tr>
<td><strong>Zinc</strong></td>
<td>mg</td>
</tr>
<tr>
<td></td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>15</td>
</tr>
</tbody>
</table>

can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/


/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/


Animal Toxicity Studies:

Non-Human Toxicity Excerpts:
/LABORATORY ANIMALS: Acute Exposure/ An aqueous (10%) solution of ascorbyl palmitate and undiluted ascorbyl dipalmitate were instilled into the conjunctival sac of albino rabbits in a modified Draize ocular irritancy test. The test volume was 0.1 mL. ascorbyl palmitate was not irritating to the eyes of rabbits, and ascorbyl dipalmitate was minimally irritating.


/LABORATORY ANIMALS: Acute Exposure/ A 10% aqueous solution of ascorbyl palmitate and undiluted ascorbyl dipalmitate were nonirritating to the intact, shaved skin of albino rabbits in a modified Draize dermal irritancy test when the test materials were applied with occlusive patches for 24 hours.


/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Rats (10 per group) were given 2% and 5% ascorbyl palmitate in feed for 9 months. Significant growth retardation occurred in rats given 5% ascorbyl palmitate, and 2 of 10 had bladder stones and hyperplasia of
the bladder epithelium. One rat of the high dose group had lesions of nephritis. Slight growth retardation occurred in rats fed the 2% diet, but no other signs of toxicity were observed.


/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Female mice fed ascorbyl palmitate for 63 days had no signs of toxicity during a tumor inhibition study at doses up to 3000 mg/kg/day.


/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Ascorbyl palmitate when topically applied at small doses inhibited 12-O-tetradecanoylphorbol-13-acetate-induced (TPA-induced) ornithine decarboxylase activity, tumor production, and DNA synthesis in mouse epithelial cell. A dose of 4 umol of ascorbyl palmitate inhibited by 60-70% after one topical application of 2 nmol TPA. When 5 nmol TPA was administered with 5 pmol ascorbyl palmitate twice weekly to previously initiated mice, 91% of tumors were inhibited per mouse.


/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Female 5-week-old CF-1 mice were either fed a control diet or a diet containing 2% ascorbyl palmitate for 2 weeks. One half of each group (12 mice per group), was injected subcutaneously with 10 mg/kg azoxymethanol in saline, which induces formation of focal areas of dysplasia (FADs), and the other half with normal saline once weekly for 6 weeks, while fed their respective diets. One week after the last injection, the mice were given intraperitoneal injections of 25 uCi [3H] thymidine in water. An hour later, the animals were sacrificed and the colons removed and processed for microscopic examination. Multiple 500 uM sections of distal colon from each mouse were examined for the number of FADs, observed as cells with variable shape and size nuclei, lack of nuclear polarity, and a loss of mucin. Oral administration of ascorbyl palmitate did not produce signs of toxicity or affect body weight. Subcutaneously administered azoxymethanol induced proliferation of colonic epithelial cells and the expansion of the proliferative compartment as well as the formation of FADs. No FADs were observed in either the control mice or those fed ascorbyl palmitate. Also, ascorbyl palmitate did not inhibit proliferation of or reduce the number of induced FADs.

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Rats (eight per group) were fed a diet of heat-treated lard containing 2% or 5% ascorbyl palmitate (equivalent to 424 mg/kg and 1060 mg/kg, or 0.05% and 0.25% of the total diet) during a 2-year study. Growth rate decreased at the higher dose, and two of eight rats had oxalate stones after 9 months of treatment. [Cosmetic Ingredient Review; Final Report of the Cosmetic Ingredient Review Expert Panel; Final Report on the Safety Assessment of Ascorbyl Palmitate, Ascorbyl Dipalmitate, Ascorbyl Stearate, Erythorbic Acid, and Sodium Erythorbate; Scientific Regulatory Reference CD-ROM (2006). Cosmetic, Toiletry, and Fragrance Association, Washington D.C.] **PEER REVIEWED**

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Rats fed 125 mg ascorbyl palmitate per kg per day for 728 days (0.25% of diet) had no harmful effects. This intake was the equivalent of 53 mg/kg of ascorbic acid per day. In the same study, however, a different group of rats had body weight decreases at dietary doses of 2500 mg/kg/day and above. The highest dose that did not cause a toxicologic effect was 1000 mg/kg/day. Additionally, oxalate stones were observed in the urinary bladders of two of the eight rats in the second group when a dose of 2500 mg/kg/day was administered. [Cosmetic Ingredient Review; Final Report of the Cosmetic Ingredient Review Expert Panel; Final Report on the Safety Assessment of Ascorbyl Palmitate, Ascorbyl Dipalmitate, Ascorbyl Stearate, Erythorbic Acid, and Sodium Erythorbate; Scientific Regulatory Reference CD-ROM (2006). Cosmetic, Toiletry, and Fragrance Association, Washington D.C.] **PEER REVIEWED**

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ ... The modifying effect of hemicalcium ascorbate (Ca-Asc), and its lipophilic derivatives, 2-O-octadecylascorbic acid (CV-3611) and ascorbyl palmitate (AscP), on hepatocarcinogenesis by 3’-methyl-4-dimethylaminoazobenzene (3’-Me-DAB) /was examined/ in ODS rats (a mutant unable to synthesize ascorbic acid). Male 14-week-old ODS rats were given a modified AIN-A diet or the diet containing 0.06% 3’-Me-DAB, and drinking water containing 0.1% ascorbic acid. Rats were divided into the following eight groups: Group 1, no treatment (basal diet alone); Group 2, Ca-Asc; Group 3, CV-3611; Group 4, AscP; Group 5, 3’-Me-DAB; Group 6, 3’-Me-DAB + Ca-Asc; Group 7, 3’-Me-DAB + CV-3611; and Group 8, 3’-Me-DAB + AscP. Ca-Asc (2 g/kg), CV-3611 (0.2 g/kg), and AscP (0.6 g/kg) was administered once every day by gavage. 3’-Me-DAB was given in the basal diet. After 17 weeks, animals were killed by exsanguination, and the liver was weighed and processed for histological examination. Treatment by CV-3611 exerted a marked inhibitory effect on the development of 3’-Me-DAB-induced hepatocellular carcinomas (HCC) as measured by multiplicity. Although less effective than CV-3611, Ca-Asc and AscP also showed inhibitory effect...
[Shimpo K et al; Cancer Detect Prev 20 (2): 137-45 (1996)] **PEER REVIEWED**
PubMed Abstract

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Rats fed 5% of a 1-ascorbyl-D-isosorbil palmitate mixture for 9 months developed bladder stones and showed retarded growth, but no effects were noted at the 2% level.
The authors performed both the Ames test, using Salmonella typhimurium strains TA98, TA100, TA1535, TA1537, and TA 1538, and the tryptophan reversion assay using Escherichia coil strain WP2. Doses of ascorbyl palmitate (dissolved in 0.067 M potassium or sodium sulfate buffer at pH 7.0) from 0.01 to 3.3 mg per plate were tested, and doses greater than 3.3 mg per plate were toxic to bacteria. In both assays, ascorbyl palmitate was nonmutagenic.

Ascorbyl palmitate (AP) markedly decreased the numbers of his+ revertants, behaving as a membrane-active antimutagen. A comparative study of the antioxidative activity of the investigated substances in the methyl oleate (MO) system has demonstrated that AA and its derivatives have pro-oxidant properties within the limits of the concentrations studied. The results obtained do not agree with the common view of the mode of action of these antimutagens, including both inhibition of free radical processes and MNNG reductive inactivation.

The mechanism of antimutagenic activity of ascorbic acid (AA) and its derivatives was studied using the Salmonella typhimurium TA100 bacterial test system. All substances studied inhibited N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced mutagenesis. Ascorbyl palmitate (AP) markedly decreased the numbers of his+ revertants, behaving as a membrane-active antimutagen. A comparative study of the antioxidative activity of the investigated substances in the methyl oleate (MO) system has demonstrated that AA and its derivatives have pro-oxidant properties within the limits of the concentrations studied. The results obtained do not agree with the common view of the mode of action of these antimutagens, including both inhibition of free radical processes and MNNG reductive inactivation.

The in vitro effect of ascorbyl esters, viz., ascorbyl-palmitate (As-P), -stearate (As-S) and mouse interferon-alpha/beta (MulFN-alpha/beta) on mouse glioma-26 cell viability, proliferation and glutathione S-transferase (GST) activity was investigated. Cell viability and proliferation were examined by colorimetric MTT assay and [3H]-thymidine incorporation, respectively. Incubation (24 hr) of G-26 cells with As-S, As-P or MulFN-alpha/beta, resulted in a dose dependent decrease in cell viability (IC50 = 125 uM As-S; 175 uM As-P and 3.6 x 10^4 U/mL MulFN-alpha/beta) and proliferation (IC50 = 157 uM As-S; 185 uM As-P and 3.6 x 10^4 U/mL MulFN-alpha/beta). A combined exposure to 175 uM As-S and 800 U/mL of MulFN-alpha/beta resulted in a greater than an additive effect on cell viability and proliferation. The inhibition of cell proliferation/viability by interferon was species specific and was observed only with homologous MulFN-alpha/beta, but not with human interferon-alpha lymphoblastoid or human interferon-beta. Ascorbyl esters inhibited cytosolic GST activity (1-50 = 15.0 uM As-S and 28.5 uM As-P) towards 1-chloro-2,4-dinitrobenzene in a dose dependent manner. The apparent Ki values for affinity purified GST, deduced from Dixon plots were 0.95 uM and 2.0 uM for As-S and As-P, respectively. Significant inhibition of GST was also observed in the cytosol isolated from G-26 cells exposed to 300 uM As-S or 800 U/mL MulFN-alpha/beta.

Effects of 6-O-palmitoyl ascorbate (ascorbate) developed to increase the antitumor activity of ascorbic acid on DNA synthesis and proliferation of Ehrlich ascites tumor cells were investigated. Treatment of the cells with the acylated ascorbate at 25-50 uM for 1 hr resulted in no effect on DNA synthesis, assayed by pulse...
incorporation of [3H]thymidine after a culture period of 20 hr, but led to 49%-87% enhanced DNA synthesis after 4 days, suggesting that long-term culture is required for promotion by ascorbate to occur. At a dose as high as 75 uM acylated ascorbate, however, cellular DNA synthesis was 64% inhibited after 20 hr and 99% after 4 days. The results suggest that acylated ascorbate exhibits a dual action on DNA synthesis: promotion at low doses and inhibition at high doses, both of which are potentiated in a time-dependent manner. In contrast to the above-mentioned results at 37 degrees C, acylated ascorbate at 25-75 uM inhibited but did not promote DNA synthesis at 42 degrees C whatever the culture period. Similar results were exhibited when proliferation of cells cultured for a long period was investigated. At 37 degrees C, 50 uM acylated ascorbate increased the number of the cells to 3.6 times the control values after 8 days and to 1.9 times after 11 days; in contrast, a 75-uM dose decreased the cell number considerably. Combination with hyperthermia (42 degrees C) suppressed the increase and cell growth was completely inhibited at 75 uM.

[Kageyama K et al; J Cancer Res Clin Oncol 122 (1): 41-4 (1996)] **PEER REVIEWED**

/ALTERNATIVE and IN VITRO TESTS/ Primary cultures of heart endothelial and muscle cells prepared from 2-5-day-old Wistar rats were exposed to heated corn oil. Thermally oxidized fats when ingested can result in toxicity signs such as altered fatty acid composition of tissue lipids, depressed growth, formation of pyknotic nuclei, and necrosis of other tissues. Those oxidized lipids also increased the severity of vitamin E deficiency. When 10 mg ascorbyl palmitate in 100 mL ethanol was emulsified and used to treat the monolayer heart cell cultures at 96 hours, the mitotic index increased, but the mean cell count values were not different. Treatment with ascorbyl palmitate also tended to prevent necrosis, but did not reduce intracellular lipidosis.


/OTHER TOXICITY INFORMATION/ The effect of some additives, phenylalanine, ascorbyl palmitate and sodium ascorbyl phosphate on the oxidation of linoleic acid and porcine ear skin induced by UV irradiation was investigated, in the absence and in the presence of variously uncoated and coated titania powders. ... Sodium ascorbyl phosphate and ascorbyl palmitate displayed a stronger antioxidant effect than phenylalanine toward linoleic acid peroxidation. On porcine skin all the three molecules exhibited both antiradical and antioxidant activity. Their protective effect against peroxidation was higher with porcine skin lipids than with linoleic acid, referable to the chemical differences in the two lipid substrates.

[Carlotti ME et al; J Photochem Photobiol B 96 (2): 130-5 (2009)] **PEER REVIEWED**

Non-Human Toxicity Values:
LD50 Guinea pig dermal >3 g/kg

LD50 Mouse oral >2 g/kg /33% suspension/

LD50 Rat oral >5 g/kg /33% suspension/

Metabolism/Pharmacokinetics:

Metabolism/Metabolites:
Vitamin C (ascorbic acid) is a non-enzymatic antioxidant important in protecting the lung against oxidative damage and is decreased in lung lining fluid of horses with airway inflammation. To examine possible therapeutic regimens in a species with ascorbate-synthesising capacity, ... Te effects of oral supplementation of two forms of ascorbic acid, (each equivalent to 20 mg ascorbic acid per kg body weight) on the pulmonary and systemic antioxidant status of six healthy ponies in a 3 x 3 Latin square design. Two weeks supplementation with ascorbyl palmitate significantly increased mean plasma ascorbic acid concentrations compared to control (29 +/- 5 and 18 +/- 7 umol/L, respectively; p < 0.05). Calcium ascorbyl-2-monophosphate, a more stable form of ascorbic acid, also increased mean plasma ascorbic acid concentrations, but not significantly (23 +/- 1 umol/L; p = 0.07). The concentration of ascorbic acid in bronchoalveolar lavage fluid increased in five out of six ponies following supplementation with either ascorbyl palmitate or calcium ascorbyl-2-monophosphate compared with control (30 +/- 10, 25 +/- 4 and 18 +/- 8 umol/L, respectively; p < 0.01). Neither supplement altered the concentration of glutathione, uric acid or alpha-tocopherol in plasma or bronchoalveolar lavage fluid. In conclusion, the concentration of lung lining fluid ascorbic acid is increased following ascorbic acid supplementation (20 mg/kg body weight) in an ascorbate-synthesising species.
[Deaton CM et al; Free Radic Res 37 (4): 461-7 (2003)] **PEER REVIEWED**

PubMed Abstract

It has been known that solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) have occlusive effects, but ascorbyl palmitate (AP) incorporation moisturized skin significantly better than placebo in short-term (p < 0.001) and long-term trials (p < 0.01) for both SLN and NLC. In the second part of the study, SLN and NLC were found to sustain the penetration of AP through excised human skin about 1/2 and 2/3 times compared to NE (p < 0.001 and p < 0.01), respectively...
[Uner M et al; Pharmazie 60 (10): 751-5 (2005)] **PEER REVIEWED**

PubMed Abstract
6-O-Palmitoyl-L-ascorbic acid dissolved in a sodium taurocholate solution was hydrolyzed by homogenates of the pancreas, liver, and intestines of guinea pigs.

INAGAKI C ET AL; VITAMINS 37(2) 147 (1968) **PEER REVIEWED**

**Absorption, Distribution & Excretion:**

When incorporated into the cell membranes of human red blood cells, ascorbyl palmitate has been found to protect them from oxidative damage and to protect alpha-tocopherol (a fat-soluble antioxidant) from oxidation by free radicals. However, the protective effects of ascorbyl palmitate on cell membranes have only been demonstrated in the test tube. Taking ascorbyl palmitate orally probably doesn't result in any significant incorporation into cell membranes because most of it appears to be hydrolyzed (broken apart into palmitate and ascorbic acid) in the human digestive tract before it is absorbed. The ascorbic acid released by the hydrolysis of ascorbyl palmitate appears to be as bioavailable as ascorbic acid alone.

[Linus Pauling Institute at Oregon State University; Micronutrient Information Center; The Bioavailability of Different Forms of Vitamin C (Ascorbic Acid). Available from, as of August 8, 2010: http://lpi.oregonstate.edu/infocenter/vitamins/vitaminC/vitCform.html **PEER REVIEWED**

When applied topically to guinea pigs, ascorbyl palmitate penetrated the skin barrier so that ascorbic acid content in the skin, liver, and blood increased eight-, seven-, and four-fold, respectively, when compared to control animals that did not receive ascorbyl palmitate.


14C-Ascorbyl palmitate was applied to the skin of scorbutic (affected by scurvy) guinea pigs. Following the topical application, ascorbic acid concentrations in the skin, liver, kidneys, and blood were four to eight times greater than in the control.


Ascorbyl palmitate dissolved in a sodium taurocholate solution was hydrolyzed by homogenates of the liver, pancreas, and intestines of guinea pigs. Approximately 80% of ascorbyl palmitate was hydrolyzed to free ascorbic acid by homogenates of the small intestine and pancreas. ... Ascorbyl palmitate (the equivalent of 20 mg of ascorbic acid) was orally administered to guinea pigs, and the amount of free ascorbic acid excreted in the urine was measured. Greater amounts of acid were excreted at 0-24 hours than at 24-48 hours. A similar trend was found in these organs of free ascorbic acid content when L-ascorbic acid was administered instead, but a reverse tendency was observed with ascorbyl palmitate.

Mechanism of Action:
... Whether L-ascorbic acid 6-palmitate (AAP), an amphipathic derivative of AA, has chemopreventive effects /was examined/ using a gap-junctional intercellular communication (GJIC) model. AAP and ascorbic acid (AA) exhibited dose-dependent free radical-scavenging activities and inhibited hydrogen peroxide (H(2)O(2))-induced intracellular reactive oxygen species (ROS) production in normal rat liver epithelial cells. Unexpectedly, however, AAP did not protect against the inhibition of GJIC induced by H(2)O(2); instead, it inhibited GJIC synergistically with H(2)O(2). AAP inhibited GJIC in a dose-dependent and reversible manner. This inhibitory effect was not due to the conjugated lipid structure of AAP, as treatment with palmitic acid alone failed to inhibit GJIC under the same conditions. The inhibition of GJIC by AAP was restored in the presence of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor U0126, but not in the presence of other signal inhibitors and antioxidant (PKC inhibitors, EGFR inhibitor, NADPH oxidase inhibitor, catalase, vitamin E, or AA), indicating the critical involvement of MEK signaling in the GJIC inhibitory activity of AAP. Phosphorylation of ERK and connexin 43 (Cx43) was observed following AAP treatment, and this was reversed by U0126. These results suggest that the AAP-induced inhibition of GJIC is mediated by the phosphorylation of Cx43 via activation of the MEK-ERK pathway.

[Lee KM et al; Mutat Res 660 (1-2): 51-6 (2009)] **PEER REVIEWED**

Interactions:
Male MEI mice in which hepatotoxicity had been induced by the feeding of 600 mg/kg acetaminophen had covalent binding of acetaminophen metabolites to hepatic proteins, a depletion of hepatic nonprotein sulphydryl groups after 2 hours, and a dramatic increase in plasma alanine aminotransferase activity after 24 hours. The coadministration of acetaminophen and ascorbyl palmitate reduced this binding within 2 and 4 hours (to 31% and 22%, respectively), reduced the depletion in nonprotein sulffhydryl groups and aminotransferase activity, and completely prevented the 35% mortality observed at 24 hours after acetaminophen treatment alone. Ascorbyl palmitate appeared to prevent hepatic damage by removing the reactive acetaminophen metabolites and by having a sparing action on reduced hepatic glutathione.


Ascorbyl palmitate when topically applied at small doses inhibited 12-O-tetradecanoylphorbol-13-acetate-induced (TPA-induced) ornithine decarboxylase activity, tumor production, and DNA synthesis in mouse epithelial cell. A dose of 4 umol of ascorbyl palmitate inhibited by 60-70% after one topical application of 2 nmol TPA. When 5 nmol TPA was administered with 5 pmol ascorbyl palmitate twice weekly to previously initiated mice, 91% of tumors were inhibited per mouse.
... This work ... sought to determine the antioxidative properties of a lipid-soluble derivative of ascorbic acid, ascorbic acid-6-palmitate. ... Ascorbic acid-6-palmitate reduced cellular levels of reactive oxygen species following ultraviolet B irradiation. Treatment of keratinocytes with ascorbic acid-6-palmitate inhibited ultraviolet-B-mediated activation of epidermal growth factor receptor, extracellular regulated kinases 1 and 2, and p38 kinase because of its ability to prevent reduced glutathione depletion and scavenge hydrogen peroxide. Ascorbic acid-6-palmitate strongly promoted ultraviolet-B-induced lipid peroxidation, c-Jun N-terminal kinase activation, and cytotoxicity, however. End products of lipid peroxidation, such as 4-hydroxy-2-nonenal, have been reported to mediate stress-activated protein kinase activation and cell toxicity in epithelial cells. The lipid component of ascorbic acid-6-palmitate probably contributes to the generation of oxidized lipid metabolites that are toxic to epidermal cells. /The/ data suggest that, despite its antioxidant properties, ascorbic acid-6-palmitate may intensify skin damage following physiologic doses of ultraviolet radiation.


... The effects of various antioxidants, including ascorbyl palmitate, on rabbit platelet functions /were studied/ by means of thromboxane B2 synthesis and enzyme immunoassay. Ascorbyl palmitate inhibited A-23187-induced thromboxane B2 synthesis at 1.0 X 10-5 M and above, and thrombin-induced synthesis at 1. X 10-7 M when added simultaneously. The pretreatment of platelets with ascorbyl palmitate also inhibited both agonist-induced syntheses unless the platelets had been stimulated with thrombin. When the rabbits were fed ADI concentrations of ascorbyl palmitate for 5 days, agonist-induced activation of platelets also was reduced considerably.


... The modifying effect of hemicalcium ascorbate (Ca-Asc), and its lipophilic derivatives, 2-O-octadecylascorbic acid (CV-3611) and ascorbyl palmitate (AscP), on hepatocarcinogenesis by 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB) /was examined/ in ODS rats (a mutant unable to synthesize ascorbic acid). Male 14-week-old ODS rats were given a modified AIN-A diet or the diet containing 0.06% 3'-Me-DAB, and drinking water containing 0.1% ascorbic acid. Rats were divided into the following eight groups: Group 1, no treatment (basal diet alone); Group 2, Ca-Asc; Group 3, CV-3611; Group 4, AscP; Group 5, 3'-Me-DAB; Group 6, 3'-Me-DAB + Ca-Asc; Group 7, 3'-Me-DAB + CV-3611; and Group 8, 3'-Me-DAB + AscP. Ca-Asc (2 g/kg), CV-3611 (0.2 g/kg), and AscP (0.6 g/kg) was administered once every day by gavage. 3'-Me-DAB was given in the basal diet. After 17 weeks, animals were killed by exsanguination, and the liver was weighed and processed for histological examination. Treatment by CV-3611 exerted a marked inhibitory effect on the development of 3'-Me-DAB-induced hepatocellular carcinomas (HCC) as measured by multiplicity. Although less effective than CV-3611, Ca-Asc
and AsCP also showed inhibitory effect...

[Shimpo K et al; Cancer Detect Prev 20 (2): 137-45 (1996)] **PEER REVIEWED**

PubMed Abstract

The chemopreventive effect of 40 and 80% maximum tolerated dose (MTD) levels of ascorbylpalmitate (AP) ... administrated in the diet before and during initiation and postinitiation phases of azoxymethane (AOM)-induced colon carcinogenesis was studied in male F344 rats. The MTD levels of AP ... were determined in male F344 rats and found to be 5000 ... ppm ... in modified AIN-76A diet. Based on these MTD values, 40 and 80% MTD levels ... were tested for their efficacy in colon carcinogenesis. At 5 weeks of age, groups of animals were fed the control (modified AIN-76A diet or diets containing 40 and 80% MTD levels of ... AP... . At 7 weeks of age, all animals, except those in the vehicle (normal saline)-treated groups, were given two weekly sc injections of AOM at a dose rate of 15 mg/kg body weight/week. All groups were continued on their respective dietary regimen until the termination of the experiment 52 weeks after the carcinogen treatment. Colonic tumors were evaluated histopathologically. The results indicate that dietary administration of 40% MTD of AP significantly inhibited multiplicities (tumor/animal) of noninvasive and total (invasive plus noninvasive) adenocarcinoma of the colon (P < 0.05) and 80% MTD of AP significantly inhibited the incidence (% animals with tumors) and the multiplicities of invasive and total adenocarcinomas of the colon (P < 0.01)...[Rao CV et al; Anticancer Res 15 (4): 1199-204 (1995)] **PEER REVIEWED**

PubMed Abstract

The effects of L-ascorbyl stearate and L-ascorbyl palmitate on carbon tetrachloride-induced alterations in glutathione and ascorbic acid content in mouse livers were investigated. Powdered food containing 1% ascorbate ester was given to mice for 3 days before and 1 day after a single injection of CCl4 (0.1 mL/kg, ip). Biochemical parameters were determined 1 day after the CCl4 administration. The ascorbate esters markedly attenuated CCl4-induced alterations such as reductions in ascorbate content and hepatic glutathione S-transferase (GST) activity, and increases in glutathione and calcium content and serum GST activity. The CCl4-induced rise in thiobarbituric acid-reactive substances, an index of lipid peroxidation, was not affected by ascorbate feeding. These findings suggest that exogenous ascorbate, in addition to endogenous glutathione, is available to maintain the intracellular milieu in a reduced state, and that this system operates more effectively in aqueous compartments than in membrane lipid bilayers.

[Nakagawa K; Arch Toxicol 67 (10): 686-90 (1993)] **PEER REVIEWED**

PubMed Abstract

Single and multiple colonic crypts exhibiting dysplasia that are detectable in situ by staining of rat colon with methylene blue are called aberrant crypts (AC) and may serve as an intermediate marker for colon cancer. ... 20 candidate chemopreventive agents /including ascorbyl palmitate were examined/ for inhibition of AC. All agents were given in AIN-76 diet, at two dose levels, with injections of AOM. AC were measured after 5 weeks of growth. Among the most active AC-inhibiting agents were ... ascorbyl palmitate. ... The AC assay shows marked sensitivity and specificity for screening agents for chemoprevention of colon cancer.


PubMed Abstract

The effect of topical application of ascorbic acid (AA) and ascorbyl palmitate (AP) on 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced tumor promotion in mouse skin was
investigated. A single application of TPA decreased epidermal AA by 45%. Repetitive application of 6 and 28 umol AA with 2 nmol TPA inhibited tumor multiplicity by 39% and 76%. Repetitive application of 0.16, 0.8, and 4.0 umol AA with 5 nmol TPA inhibited tumor multiplicity by 16%, 46%, and 91%. Because AA may be poorly absorbed cutaneously, the effect of dietary AA was examined. Supplementation of drinking water with AA increased epidermal ascorbic acid levels by 50%. Dietary intake of AA did not inhibit TPA-induced tumor promotion.

[Smart RC, Crawford CL; Am J Clin Nutr 54 (6 Suppl): 1266S-1273S (1991)]

Acetaminophen (APAP) with or without ascorbyl stearate (AS) or ascorbyl palmitate (AP) was administered by gavage to male Swiss-Webster mice at a dose of 600 mg/kg for each chemical. The biochemical markers of hepatotoxicity, serum transaminases (serum glutamate pyruvate transaminase [SGPT], serum glutamate oxaloacetic transaminase [SGOT]) and serum isocitrate dehydrogenase (SCID) activities were monitored after APAP and APAP + AP or AS dosing. There were significant reductions in serum transaminase and SCID activities in the APAP- + ascorbate ester-treated animals as compared to APAP-positive controls. Oral coadministration of APAP with AP or AS did not prevent the initial hepatic GSH depletion (15 min-4 hr postdosing). However, hepatic GSH content began to rise in the APAP + AS or AP-treated animals at 4 hr and reached control values within 12 hr postdosing. Urinary mercapturate conjugates were also significantly higher in the APAP + AP or AS-treated animals as compared to APAP alone when measured over a 60-min postdosing period. Plasma sulfobromophthalein (BSP) retention was approximately eight times higher in APAP-treated animals as compared to the APAP + ascorbate ester treatments indicating maintenance of hepatic excretory functions in presence of AP or AS. Prior depletion of hepatic GSH by diethyl maleate (DEM) did not alter hepatoprotective effects of AP or AS in the presence of APAP. Hepatic ascorbate levels also peaked at 4 hours after APAP + AP or AS treatments. The possible role of L-ascorbic acid esters in GSH regeneration following co-administration of a hepatotoxic dose and APAP is discussed.

[Mitra A et al; J Biochem Toxicol 6 (2): 93-100 (1991)]

The effects of ascorbyl palmitate (ASCP) and free L-ascorbic acid (LAA) on the hepatotoxicity of paracetamol (acetaminophen) and the in vivo covalent binding of reactive paracetamol metabolites to hepatic proteins has been studied in male MF1 mice. The oral administration of [3H(G)]paracetamol (600 mg/kg) resulted in covalent binding to hepatic proteins, a depletion of hepatic non-protein sulphhydril (NPS) groups after 2 hr, and a marked elevation of plasma alanine aminotransferase (ALAT) activity after 24 hr. The co-administration of paracetamol and ASCP (1412 mg/kg, equivalent to 600 mg/kg free LAA), but not paracetamol and LAA (600 mg/kg), significantly reduced covalent binding of paracetamol metabolites at 2 and 4 hr after treatment. In addition ASCP, but not LAA, significantly reduced the depletion of NPS groups and the elevation of plasma ALAT activity. ASCP also completely prevented the 35% mortality observed at 24 hr in paracetamol treated mice. These results demonstrate that ASCP, but not LAA, when co-administered orally with the analgesic is an effective inhibitor of paracetamol-induced hepatotoxicity in the mouse. The mechanism by which ASCP prevents liver injury appears to involve destruction of reactive paracetamol metabolites which is associated with a sparing action on hepatic reduced glutathione levels.

[Jonker D et al; Toxicology 52 (3): 287-95 (1988)]
Groups of male Swiss-Webster mice were gavaged with acetaminophen (APAP), APAP + ascorbyl stearate (AS), or APAP + ascorbyl palmitate (AP) at a dose of 600 mg/kg for each chemical. APAP alone caused a significant increase in liver weight/body weight ratio and hepatic glutathione (GSH) depletion. Co-administration of the ascorbate esters AP or AS with APAP prevented an increase in liver weight/body weight ratios and hepatic glutathione depletion. APAP + AS treatments caused significantly greater reductions in rectal temperature at 15-30 min post-dosing periods when compared to APAP + AP or AS treatments. Blood levels of APAP had the same relationship. The study indicates a correlation between APAP blood levels and antipyretic effect of APAP + AS and APAP + AP coadministrations. While both ascorbate esters probably afford protection against APAP-induced hepatotoxicity in mice by reducing the reactive intermediate back to the parent compound, the APAP + AS combination provides better therapeutic efficacy as an antipyretic at the 15-30 min post-dosing periods.


Bromobenzene undergoes metabolic activation via 2,3- and 3,4-epoxidation catalyzed by the hepatic cytochrome P-450 mixed-function oxidase system. Its reactive metabolites, especially bromobenzene 3,4-oxide, presumably lead to severe centrolobular necrosis. A study of relative rate of binding of 14C-bromobenzene metabolites to hepatic microsomal protein indicated a significant difference in the rate of binding of the bromobenzene 3,4-oxide compared to its positional isomer, bromobenzene 2,3-oxide. However, the rate of bromobenzene metabolism indicated no significant difference in the formation of products o-bromophenol and p-bromophenol. A search for protective agents revealed that 6,7-dimethyl-5,6,7,8-tetrahydropterine and ascorbyl palmitate were very effective in protecting against macromolecular adduct formation at a concentration of 1 mM—in fact, at least a twofold increase in protection compared to the known protective agents such as glutathione or cysteine. Furthermore, 6,7-dimethyl-5,6,7,8-tetrahydropterine and ascorbyl palmitate inhibited the metabolism of bromobenzene over 90% at a concentration of 2.5 mM.

[Zannoni VG et al; Drug Nutr Interact 1 (3): 193-204 (1982).] **PEER REVIEWED**

The nitrosation of dipropylamine and pyrrolidine were examined in 2 phase systems comprising aqueous buffer and non-polar solvent. Ascorbyl palmitate generally reduced nitrosation.

[Motttram DS; Patterson RLS; J Sci Food Agric 20(4) 352 (1977)] **PEER REVIEWED**

Pharmacology:

Therapeutic Uses:
Antimutagenic Agents; Antioxidants
[National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)] **PEER REVIEWED**

Ascorbyl palmitate has a vitamin C activity approximately equal to that of L-ascorbic acid. ... Vitamin C is an essential cofactor for prolyl and lysyl hydroxylases, the enzymes involved in the
intracellular biosynthesis of collagen.


/Experimental Therapy/ QR-333, a topical compound that contains quercetin, a flavonoid with aldose reductase inhibitor effects, ascorbyl palmitate, and vitamin D(3), was formulated to decrease the oxidative stress that contributes to peripheral diabetic neuropathy and thus alleviate its symptoms. ... This randomized, placebo-controlled, double-blind trial included 34 men and women (21-71 years of age) with Type 1 or 2 diabetes and diabetic neuropathy who applied QR-333 or placebo (2:1 ratio), three times daily for 4 weeks, to each foot where symptoms were experienced. ... QR-333 reduced the severity of numbness, jolting pain, and irritation from baseline values. Improvements were also seen in overall and specific quality-of-life measures. QR-333 was well tolerated. Eleven patients in the QR-333 group reported 23 adverse events (all mild or moderate); 4 in the placebo group reported 5 events (all moderate). One patient who applied QR-333 noted a pricking sensation twice, the only adverse event considered possibly related to study treatment...


The presence of ascorbyl palmitate in oral supplements contributes to the ascorbic acid content of the supplement and probably helps protect fat-soluble antioxidants in the supplement.

[ Linus Pauling Institute at Oregon State University; Micronutrient Information Center; The Bioavailability of Different Forms of Vitamin C (Ascorbic Acid). Available from, as of August 8, 2010: http://lpi.oregonstate.edu/infocenter/vitamins/vitaminC/vitCform.html ] **PEER REVIEWED**

Interactions:
Male MEl mice in which hepatotoxicity had been induced by the feeding of 600 mg/kg acetaminophen had covalent binding of acetaminophen metabolites to hepatic proteins, a depletion of hepatic nonprotein sulphydryl groups after 2 hours, and a dramatic increase in plasma alanine aminotransferase activity after 24 hours. The coadministration of acetaminophen and ascorbyl palmitate reduced this binding within 2 and 4 hours (to 31% and 22%, respectively), reduced the depletion in nonprotein sulfhydryl groups and aminotransferase activity, and completely prevented the 35% mortality observed at 24 hours after acetaminophen treatment alone. Ascorbyl palmitate appeared to prevent hepatic damage by removing the reactive acetaminophen metabolites and by having a sparing action on reduced hepatic glutathione.


Ascorbyl palmitate when topically applied at small doses inhibited 12-O-tetradecanoylphorbol-13-acetate-induced (TPA-induced) ornithine decarboxylase activity, tumor production, and DNA synthesis in mouse epithelial cell. A dose of 4 umol of ascorbyl palmitate inhibited by 60-70%
after one topical application of 2 nmol TPA. When 5 nmol TPA was administered with 5 pmol ascorbyl palmitate twice weekly to previously initiated mice, 91% of tumors were inhibited per mouse.


... This work sought to determine the antioxidative properties of a lipid-soluble derivative of ascorbic acid, ascorbic acid-6-palmitate. ... Ascorbic acid-6-palmitate reduced cellular levels of reactive oxygen species following ultraviolet B irradiation. Treatment of keratinocytes with ascorbic acid-6-palmitate inhibited ultraviolet-B-mediated activation of epidermal growth factor receptor, extracellular regulated kinases 1 and 2, and p38 kinase because of its ability to prevent reduced glutathione depletion and scaveng hydrogen peroxide. Ascorbic acid-6-palmitate strongly promoted ultraviolet-B-induced lipid peroxidation, c-Jun N-terminal kinase activation, and cytotoxicity, however. End products of lipid peroxidation, such as 4-hydroxy-2-nonenal, have been reported to mediate stress-activated protein kinase activation and cell toxicity in epithelial cells. The lipid component of ascorbic acid-6-palmitate probably contributes to the generation of oxidized lipid metabolites that are toxic to epidermal cells. /The/ data suggest that, despite its antioxidant properties, ascorbic acid-6-palmitate may intensify skin damage following physiologic doses of ultraviolet radiation.


... The effects of various antioxidants, including ascorbyl palmitate, on rabbit platelet functions were studied by means of thromboxane B2 synthesis and enzyme immunoassay. Ascorbyl palmitate inhibited A-23187-induced thromboxane B2 synthesis at 1.0 X 10-5 M and above, and thrombin-induced synthesis at 1. X 10-7 M when added simultaneously. The pretreatment of platelets with ascorbyl palmitate also inhibited both agonist-induced syntheses unless the platelets had been stimulated with thrombin. When the rabbits were fed ADI concentrations of ascorbyl palmitate for 5 days, agonist-induced activation of platelets also was reduced considerably.


... The modifying effect of hemicalcium ascorbate (Ca-Asc), and its lipophilic derivatives, 2-O-octadecylascorbic acid (CV-3611) and ascorbyl palmitate (AscP), on hepatocarcinogenesis by 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB) was examined in ODS rats (a mutant unable to synthesize ascorbic acid). Male 14-week-old ODS rats were given a modified AIN-A diet or the diet containing 0.06% 3'-Me-DAB, and drinking water containing 0.1% ascorbic acid. Rats were divided into the following eight groups: Group 1, no treatment (basal diet alone); Group 2, Ca-Asc; Group 3, CV-3611; Group 4, AscP; Group 5, 3'-Me-DAB; Group 6, 3'-Me-DAB + Ca-Asc; Group 7, 3'-Me-DAB + CV-3611; and Group 8, 3'-Me-DAB + AscP. Ca-Asc (2 g/kg), CV-3611 (0.2 g/kg), and AscP (0.6 g/kg) was administered once every day by gavage. 3'-Me-DAB was given in the basal diet. After 17 weeks, animals were killed by exsanguination,
and the liver was weighed and processed for histological examination. Treatment by CV-3611 exerted a marked inhibitory effect on the development of 3'-Me-DAB-induced hepatocellular carcinomas (HCC) as measured by multiplicity. Although less effective than CV-3611, Ca-Asc and AscP also showed inhibitory effect...


The chemopreventive effect of 40 and 80% maximum tolerated dose (MTD) levels of ascorbylpalmitate (AP) ... administrated in the diet before and during initiation and postinitiation phases of azoxymethane (AOM)-induced colon carcinogenesis was studied in male F344 rats. The MTD levels of AP ... were determined in male F344 rats and found to be 5000 ... ppm ... in modified AIN-76A diet. Based on these MTD values, 40 and 80% MTD levels ... were tested for their efficacy in colon carcinogenesis. At 5 weeks of age, groups of animals were fed the control (modified AIN-76A diet or diets containing 40 and 80% MTD levels of ... AP.... At 7 weeks of age, all animals, except those in the vehicle (normal saline)-treated groups, were given two weekly sc injections of AOM at a dose rate of 15 mg/kg body weight/week. All groups were continued on their respective dietary regimen until the termination of the experiment 52 weeks after the carcinogen treatment. Colonic tumors were evaluated histopathologically. The results indicate that dietary administration of 40% MTD of AP significantly inhibited multiplicities (tumor/animal) of noninvasive and total (invasive plus noninvasive) adenocarcinoma of the colon (P < 0.05) and 80% MTD of AP significantly inhibited the incidence (% animals with tumors) and the multiplicities of invasive and total adenocarcinomas of the colon (P < 0.01)...


The effects of L-ascorbyl stearate and L-ascorbyl palmitate on carbon tetrachloride-induced alterations in glutathione and ascorbic acid content in mouse livers were investigated. Powdered food containing 1% ascorbate ester was given to mice for 3 days before and 1 day after a single injection of CCl4 (0.1 mL/kg, ip). Biochemical parameters were determined 1 day after the CCl4 administration. The ascorbate esters markedly attenuated CCl4-induced alterations such as reductions in ascorbate content and hepatic glutathione S-transferase (GST) activity, and increases in glutathione and calcium content and serum GST activity. The CCl4-induced rise in thiobarbituric acid-reactive substances, an index of lipid peroxidation, was not affected by ascorbate feeding. These findings suggest that exogenous ascorbate, in addition to endogenous glutathione, is available to maintain the intracellular milieu in a reduced state, and that this system operates more effectively in aqueous compartments than in membrane lipid bilayers.


Single and multiple colonic crypts exhibiting dysplasia that are detectable in situ by staining of rat colon with methylene blue are called aberrant crypts (AC) and may serve as an intermediate marker for colon cancer. ... 20 candidate chemopreventive agents /including ascorbyl palmitate were examined/ for inhibition of AC. All agents were given in AIN-76 diet, at two dose levels, with injections of AOM. AC were measured after 5 weeks of growth. Among the most active AC-inhibiting agents were ... ascorbyl palmitate. ... The AC assay shows marked sensitivity and specificity for screening agents for chemoprevention of colon cancer.

The effect of topical application of ascorbic acid (AA) and ascorbyl palmitate (AP) on 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced tumor promotion in mouse skin was investigated. A single application of TPA decreased epidermal AA by 45%. Repetitive application of 6 and 28 umol AA with 2 nmol TPA inhibited tumor multiplicity by 39% and 76%. Repetitive application of 0.16, 0.8, and 4.0 umol AA with 5 nmol TPA inhibited tumor multiplicity by 16%, 46%, and 91%. Because AA may be poorly absorbed cutaneously, the effect of dietary AA was examined. Supplementation of drinking water with AA increased epidermal ascorbic acid levels by 50%. Dietary intake of AA did not inhibit TPA-induced tumor promotion...


Acetaminophen (APAP) with or without ascorbyl stearate (AS) or ascorbyl palmitate (AP) was administered by gavage to male Swiss-Webster mice at a dose of 600 mg/kg for each chemical. The biochemical markers of hepatotoxicity, serum transaminases (serum glutamate pyruvate transaminase [SGPT], serum glutamate oxaloacetatic transaminase [SGOT]) and serum isocitrate dehydrogenase (SICD) activities were monitored after APAP and APAP + AP or AS dosing. There were significant reductions in serum transaminase and SICD activities in the APAP- and ascorbate ester-treated animals as compared to APAP-positive controls. Oral coadministration of APAP with AP or AS did not prevent the initial hepatic GSH depletion (15 min-4 hr postdosing). However, hepatic GSH content began to rise in the APAP + AS or AP-treated animals at 4 hr and reached control values within 12 hr postdosing. Urinary mercapturate conjugates were also significantly higher in the APAP + AP or AS-treated animals as compared to APAP alone when measured over a 60-min postdosing period. Plasma sulfobromophthalein (BSP) retention was approximately eight times higher in APAP-treated animals as compared to the APAP + ascorbate ester treatments indicating maintenance of hepatic excretory functions in presence of AP or AS. Prior depletion of hepatic GSH by diethyl maleate (DEM) did not alter hepatoprotective effects of AP or AS in the presence of APAP. Hepatic ascorbate levels also peaked at 4 hours after APAP + AP or AS treatments. The possible role of L-ascorbic acid esters in GSH regeneration following co-administration of a hepatotoxic dose and APAP is discussed.


The effects of ascorbyl palmitate (ASCP) and free L-ascorbic acid (LAA) on the hepatotoxicity of paracetamol (acetaminophen) and the in vivo covalent binding of reactive paracetamol metabolites to hepatic proteins has been studied in male MF1 mice. The oral administration of [3H(G)]paracetamol (600 mg/kg) resulted in covalent binding to hepatic proteins, a depletion of hepatic non-protein sulphhydryl (NPS) groups after 2 hr, and a marked elevation of plasma alanine aminotransferase (ALAT) activity after 24 hr. The co-administration of paracetamol and ASCP (1412 mg/kg, equivalent to 600 mg/kg free LAA), but not paracetamol and LAA (600 mg/kg), significantly reduced covalent binding of paracetamol metabolites at 2 and 4 hr after treatment. In addition ASCP, but not LAA, significantly reduced the depletion of NPS groups and the elevation of plasma ALAT activity. ASCP also completely prevented the 35% mortality observed at 24 hr in paracetamol treated mice. These results demonstrate that ASCP, but not LAA, when co-administered orally with the analgesic is an effective inhibitor of paracetamol-induced hepatotoxicity in the mouse. The mechanism by which ASCP prevents liver injury
appears to involve destruction of reactive paracetamol metabolites which is associated with a 
sparing action on hepatic reduced glutathione levels.
[Jonker D et al; Toxicology 52 (3): 287-95 (1988)] **PEER REVIEWED** PubMed
Abstract

Groups of male Swiss-Webster mice were gavaged with acetaminophen (APAP), APAP +
ascorbil stearate (AS), or APAP + ascorbyl palmitate (AP) at a dose of 600 mg/kg for each
chemical. APAP alone caused a significant increase in liver weight/body weight ratio and hepatic
glutathione (GSH) depletion. Co-administration of the ascorbate esters AP or AS with APAP
prevented an increase in liver weight/body weight ratios and hepatic glutathione depletion.
APAP + AS treatments caused significantly greater reductions in rectal temperature at 15-30 min
post-dosing periods when compared to APAP + AP or AS treatments. Blood levels of APAP had
the same relationship. The study indicates a correlation between APAP blood levels and
antipyretic effect of APAP + AS and APAP + AP coadministrations. While both ascorbate esters
probably afford protection against APAP-induced hepatotoxicity in mice by reducing the
reactive intermediate back to the parent compound, the APAP + AS combination provides better
therapeutic efficacy as an antipyretic at the 15-30 min post-dosing periods.
Abstract

Bromobenzene undergoes metabolic activation via 2,3- and 3,4-epoxidation catalyzed by the
hepatic cytochrome P-450 mixed-function oxidase system. Its reactive metabolites, especially
bromobenzene 3,4-oxide, presumably lead to severe centrolobular necrosis. A study of relative
rate of binding of 14C-bromobenzene metabolites to hepatic microsomal protein indicated a
significant difference in the rate of binding of the bromobenzene 3,4-oxide compared to its
positional isomer, bromobenzene 2,3-oxide. However, the rate of bromobenzene metabolism
indicated no significant difference in the formation of products o-bromophenol and p-
bromophenol. A search for protective agents revealed that 6,7-dimethyl-5,6,7,8-tetrahydropterine
and ascorbyl palmitate were very effective in protecting against macromolecular adduct
formation at a concentration of 1 mM-in fact, at least a twofold increase in protection compared
to the known protective agents such as glutathione or cysteine. Furthermore, 6,7-dimethyl-
5,6,7,8-tetrahydropterine and ascorbyl palmitate inhibited the metabolism of bromobenzene
over 90% at a concentration of 2.5 mM.
Abstract

The nitrosation of dipropylamine and pyrrolidine were examined in 2 phase systems comprising
aqueous buffer and non-polar solvent. Ascorbyl palmitate generally reduced nitrosation.
[MOTTRAM DS; PATTERSON RLS; J SCI FOOD AGRIC 20(4) 352 (1977)] **PEER REVIEWED**

Environmental Fate & Exposure:

Environmental Fate/Exposure Summary:
Ascorbyl palmitate’s production and use as an antioxidant and as a chemical preservative food
additive may result in its release to the environment through various waste streams. If released to
air, an estimated vapor pressure of 2.09X10-15 mm Hg at 25 deg C indicates ascorbyl palmitate will exist solely in the particulate phase in the atmosphere. Particulate-phase ascorbyl palmitate will be removed from the atmosphere by wet or dry deposition. Ascorbyl palmitate does not contain chromophores that absorb at wavelengths >290 nm, and therefore is not expected to be susceptible to direct photolysis by sunlight. If released to soil, ascorbyl palmitate is expected to have moderate mobility based upon an estimated Koc of 450. Volatilization from moist soil surfaces is not expected to be an important fate process based upon an estimated Henry's Law constant of 1.4X10-7 atm·cu m/mole. Biodegradation data were not available. If released into water, ascorbyl palmitate is expected to adsorb to suspended solids and sediment based upon the estimated Koc. Volatilization from water surfaces is not expected to be an important fate process based upon this compound's estimated Henry's Law constant. An estimated BCF of 180 suggests the potential for bioconcentration in aquatic organisms is high, provided the compound is not metabolized by the organism. An estimated base-catalyzed second-order hydrolysis rate constant of 2.85X10^{-2} L/mole·sec corresponds to half-lives of 7.7 years and 280 days at pH values of 7 and 8, respectively. Occupational exposure to ascorbyl palmitate may occur through inhalation and dermal contact with this compound at workplaces where ascorbyl palmitate is produced or used. Use data indicate that the general population may be exposed to ascorbyl palmitate via ingestion of food and via use of pharmaceutical products and antioxidants containing ascorbyl palmitate. (SRC)  

**PEER REVIEWED**

Probable Routes of Human Exposure:
NIOSH (NOES Survey 1981-1983) has statistically estimated that 3,051 workers (1,122 of these were female) were potentially exposed to ascorbyl palmitate in the US(1). Occupational exposure to ascorbyl palmitate may occur through inhalation and dermal contact with this compound at workplaces where ascorbyl palmitate is produced or used. Use data indicate that the general population may be exposed to ascorbyl palmitate via ingestion of food and via use of pharmaceutical products and antioxidants containing ascorbyl palmitate. (SRC)


Artificial Pollution Sources:
Ascorbyl palmitate's production and use as an antioxidant and as a chemical preservative food additive(1) may result in its release to the environment through various waste streams(SRC).


Environmental Fate:
TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 450(SRC), determined from a structure estimation method(2), indicates that ascorbyl palmitate
is expected to have moderate mobility in soil (SRC). Volatilization of **ascorbyl palmitate** from moist soil surfaces is not expected to be an important fate process (SRC) given an estimated Henry's Law constant of 1.4X10-7 atm-cu m/mole (SRC), using a fragment constant estimation method (3). **Ascorbyl palmitate** is not expected to volatilize from dry soil surfaces (SRC) based upon an estimated vapor pressure of 2.09X10-15 mm Hg at 25 deg C (SRC), determined from a fragment constant method (4). Biodegradation data in soil were not available (SRC, 2010).


**AQUATIC FATE:** Based on a classification scheme (1), an estimated Koc value of 450 (SRC), determined from a structure estimation method (2), indicates that **ascorbyl palmitate** is expected to adsorb to suspended solids and sediment (SRC). Volatilization from water surfaces is not expected (3) based upon an estimated Henry's Law constant of 1.4X10-7 atm-cu m/mole (SRC), developed using a fragment constant estimation method (4). According to a classification scheme (5), an estimated BCF of 180 (SRC), from an estimated log Kow of 6.0 (6) and a regression-derived equation (2), suggests the potential for bioconcentration in aquatic organisms is high, provided the compound is not metabolized by the organism (SRC). Biodegradation data in water were not available (SRC, 2010).


**ATMOSPHERIC FATE:** According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere (1), **ascorbyl palmitate**, which has an estimated vapor pressure of 2.09X10-15 mm Hg at 25 deg C (SRC), determined from a fragment constant method (2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase **ascorbyl palmitate** may be removed from the air by wet or dry deposition (SRC). **Ascorbyl palmitate** does not contain chromophores that absorb at wavelengths >290 nm (3), and therefore is not expected to be susceptible to direct photolysis by sunlight (SRC).


**Environmental Abiotic Degradation:**
A base-catalyzed second-order hydrolysis rate constant of 2.85X10-2 L/mole-sec (SRC) was estimated using a structure estimation method (1); this corresponds to half-lives of 7.7 years and 280 days at pH values of 7 and 8, respectively (1). **Ascorbyl palmitate** does not contain chromophores that absorb at wavelengths >290 nm (2), and therefore is not expected to be
susceptible to direct photolysis by sunlight (SRC).


Environmental Bioconcentration:
An estimated BCF of 180 was calculated in fish for ascorbyl palmitate (SRC), using an estimated log Kow of 6.0(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is high(SRC), provided the compound is not metabolized by the organism(SRC).


Soil Adsorption/Mobility:
Using a structure estimation method based on molecular connectivity indices(1), the Koc of ascorbyl palmitate can be estimated to be 450(SRC). According to a classification scheme(2), this estimated Koc value suggests that ascorbyl palmitate is expected to have moderate mobility in soil.


Volatilization from Water/Soil:
The Henry's Law constant for ascorbyl palmitate is estimated as 1.4X10-7 atm-cu m/mole(SRC) using a fragment constant estimation method(1). This Henry's Law constant indicates that ascorbyl palmitate is expected to be essentially nonvolatile from water surfaces(2). Ascorbyl palmitate is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 2.09X10-15 mm Hg(SRC), determined from a fragment constant method(3).


Environmental Standards & Regulations:

FIFRA Requirements:
Residues of ascorbyl palmitate are exempted from the requirement of a tolerance when used in accordance with good agricultural practice as inert (or occasionally active) ingredients in
pesticide formulations applied to growing crops or to raw agricultural commodities after harvest. Use: preservative.


Residues of ascorbyl palmitate are exempted from the requirement of a tolerance when used in accordance with good agricultural practice as inert (or occasionally active) ingredients in pesticide formulations applied to animals. Use: preservative.


FDA Requirements:

Ascorbyl palmitate used as a chemical preservative in food for human consumption is generally recognized as safe when used in accordance with good manufacturing practice.


Ascorbyl palmitate used as a chemical preservative in animal drugs, feeds, and related products is generally recognized as safe when used in accordance with good manufacturing or feeding practice.


Allowable Tolerances:

Residues of ascorbyl palmitate are exempted from the requirement of a tolerance when used in accordance with good agricultural practice as inert (or occasionally active) ingredients in pesticide formulations applied to growing crops or to raw agricultural commodities after harvest. Use: preservative.


Residues of ascorbyl palmitate are exempted from the requirement of a tolerance when used in accordance with good agricultural practice as inert (or occasionally active) ingredients in pesticide formulations applied to animals. Use: preservative.


Chemical/Physical Properties:
Molecular Formula: C22-H38-O7

Molecular Weight: 414.533

Color/Form: White or yellowish white powder

Odor: Citrus-like

Melting Point: 112 deg C

Octanol/Water Partition Coefficient: log Kow = 6.00 (est)

Solubilities: Soluble in alcohol, animal oil, and vegetable oil; slightly soluble in water

In water, 7.44X10-2 mg/L at 25 deg C (est)

Spectral Properties: Specific optical rotation: +23 deg at 20 deg C, c = 1 in ethanol
[Aldrich; Handbook of Fine Chemicals and Laboratory Equipment. 2009-2010.]

28
Vapor Pressure:
2.09X10^-15 mm Hg at 25 deg C (est)
[US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.0. Jan, 2009. Available from, as of May 21, 2010:
http://www.epa.gov/oppt/exposure/pubs/episuitedl.htm **PEER REVIEWED**]

Other Chemical/Physical Properties:
Weight/volume conversion: 16.92 mg/cu m approximately equal to 1 ppm

Henry's Law constant = 1.40X10^-7 atm-cu m/mol at 25 deg C (est)
[US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.0. Jan, 2009. Available from, as of May 21, 2010:
http://www.epa.gov/oppt/exposure/pubs/episuitedl.htm **PEER REVIEWED**]

Base-catalyzed second-order hydrolysis reaction rate constant = 2.85X10^-2 L/mol-sec at 25 deg C (est)
[US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.0. Jan, 2009. Available from, as of May 21, 2010:
http://www.epa.gov/oppt/exposure/pubs/episuitedl.htm **PEER REVIEWED**]

Chemical Safety & Handling:

Disposal Methods:
SRP: Criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
**PEER REVIEWED**

Occupational Exposure Standards:

Manufacturing/Use Information:

Major Uses:
Ascorbyl palmitate is an antioxidant. It is used as a chemical preservative food additive and as an antioxidant in pharmaceuticals. ...Its use as a preservative in margarine is limited to 0.02% percent by weight of the finished food. Ascorbyl palmitate in foods prevents rancidity and the
browning of cut apples. It is also used in meat curing, to preserve canned and frozen foods.

Source of vitamin C; stabilizer; emulsifier

ANTIOXIDANT SYNERGIST IN FATS & OILS

Medication

Manufacturers:

A.M. Todd Company, 1717 Douglas Avenue, Kalamazoo, MI 49007, U.S.A.

ChemPacific Corporation, 6200 Freeport Center, Baltimore, MD 21224, U.S.A.

Crystal Chemie Pvt. Ltd., 3810/09/11 GIDC Industrial Estate Ankleshwar Bharuch, Gujarat 393002, India

Danisco A/S, Langebrogade 1 1001 Copenhagen, Denmark

Danisco Brasil Ltda., Rodovia Raposo Tavares km 27.2 06707-000 Cotia (SP), Brazil

Gangwal Chemicals Pvt. Ltd., 306, Business Classic, Chincholi Bunder Road, Malad West Mumbai 400.064, India
Hangzhou Fuyuan Fabric Material Co., Ltd. (Hangzhou Garden Trading Co), Sanxin Mansion, 7/F, 33-35, Xintang Road Hangzhou, Zhejiang 310020, China

Hawkins, Inc., 3100 East Hennepin Ave., Minneapolis, MN 55413, U.S.A.

Huzhou Longs Biochem Co., Ltd., Room C213, 699 Qingtong Road Huzhou City, Zhejiang Province 313000, China

Jiangxi Liming Pharmaceutical Factory, Liming Road Jingdezhen City, Jiangxi Province 333032, China

Kaiyuan Hengtai Fine Chemicals Factory, 33 Zhaogong North Street Shenyang City 110026, China

Liaoyang Zhongnuo Chemical Industry Co., Ltd., 248 Zhenxing Road, Taizihe District Liaoyang City, Liaoning Province 110000, China

Merck KGaA - Performance & Life Science Chemicals, Frankfurter Strasse 250 34271 Darmstadt, Germany
Nikko Chemicals Co. Ltd., 1-4-8 Nihonbashi-Bakurocho, Chuoku Tokyo 103-0002, Japan

Shanghai Sunve Pharmaceutical Co. Ltd., 22/F, Sunve Building, 356 Aomen Road Shanghai 200060, China

Spec-Chem Industries, 90 East Zhongshan Road Nanjing 210002, China

Urmila Chemopharma (P) Ltd., 1 Kiran, Dada Patil Road, Opp. Pethe, Jewellers, Naupada Thane, Mumbai 400.602, India

Yasho Industries Pvt. Ltd., 31-H, Laxmi Industrial Estate, New Link Road, Andheri West Mumbai, Maharashtra 400.053, India

Zhejiang Ruibang Laboratories, 48 Feixia Road Wenzhou 325027, China

Zhejiang Tianxin Pharmaceutical Co., Ltd., 215 Fengze Road Tiantai County, Zhejiang Province 317200, China

Methods of Manufacturing:
**Ascorbyl palmitate** is prepared by condensing palmitoyl chloride and ascorbic acid in the presence of a dehydrochlorinating agent such as pyridine. It is also formed in the reaction of L-
ascorbic acid and palmitic acid.

General Manufacturing Information:
**Ascorbyl palmitate** is an antioxidant in foods containing vegetable oil and animal fats; more recently it has appeared in the neautraceutical pantheon under the name "ester-C."

Active compounds can be protected against degradation by incorporation into colloidal carrier systems. The stabilizing effect of carrier systems for **ascorbyl palmitate** (AP) was investigated using microemulsions (ME), liposomes and solid lipid nanoparticles (SLN). Analysis of chemical stability by HPLC showed that AP is most resistant against oxidation in non-hydrogenated soybean lecithin liposomes, followed by SLN, w/o and o/w ME, and hydrogenated soybean lecithin liposomes...
PubMed Abstract

Ascorbic acid (AA), also known as vitamin C, is a very popular skin-whitening agent used in cosmetics. However, the use of AA (and also its sodium or magnesium salts) in cosmetic products is limited owing to its labile oxidative properties. In order to avoid its early degradation, different derivatives have been designed, such as ascorbyl phosphate (APH; as magnesium or sodium salts) and **ascorbyl palmitate** (AP), and more recently the ascorbyl glucoside (AG).

Formulations/Preparations:
Grade: FCC (Foods Chemical Codex).

Impurities:
The National Formulary states that **ascorbyl palmitate** must contain between 95.0% and 100.5% of C22H38O7, based on the dried weight. Depending on the method of manufacture, **ascorbyl palmitate** could contain stearic acid, because palmitic acid samples contain large quantities of stearic acid.
Consumption Patterns:
100% AS AN ANTIOXIDANT SYNERGIST IN FATS & OILS (1973)
[SRI] **PEER REVIEWED**

U. S. Production:
(1972) LESS THAN 4.54X10^5 GRAMS
[SRI] **PEER REVIEWED**

(1975) LESS THAN 4.54X10^5 GRAMS
[SRI] **PEER REVIEWED**

U. S. Imports:
(1972) No Data
[SRI] **PEER REVIEWED**

(1975) No Data
[SRI] **PEER REVIEWED**

U. S. Exports:
(1972) No Data
[SRI] **PEER REVIEWED**

(1975) No Data
[SRI] **PEER REVIEWED**

Laboratory Methods:

Special References:

Synonyms and Identifiers:

Related HSDB Records:
818 [Ascorbic acid] (METABOLITE)

Synonyms:
L-Ascorbic acid, 6-hexadecanoate
**PEER REVIEWED**
Ascorbic acid palmitate
**PEER REVIEWED**

L-Ascorbic acid, 6-palmitate
**PEER REVIEWED**

Ascorbic acid palmitate (ester)
**PEER REVIEWED**

Ascorbic palmitate
**PEER REVIEWED**

Ascorbyl monopalmitate
**PEER REVIEWED**

L-Ascorbyl monopalmitate
**PEER REVIEWED**

L-Ascorbyl palmitate
**PEER REVIEWED**

L-Ascorbyl 6-palmitate
**PEER REVIEWED**

Ascorbylpalmitic acid
**PEER REVIEWED**

Cetyl ascorbate
**PEER REVIEWED**

6-Hexadecanoyl-L-ascorbic acid
**PEER REVIEWED**

6-Monopalmitoyl-L-asorbate
**PEER REVIEWED**

Ondascora
**PEER REVIEWED**

Palmitoyl-L-ascorbic acid
**PEER REVIEWED**

6-O-Palmitoylascorbic acid
**PEER REVIEWED**

6-Palmitoylascorbic acid
**PEER REVIEWED**

Quicifal
**PEER REVIEWED**
Formulations/Preparations:
Grade: FCC (Foods Chemical Codex).

Administrative Information:

Hazardous Substances Databank Number: 418

Last Revision Date: 20110104

Last Review Date: Reviewed by SRP on 9/23/2010

Update History:
Complete Update on 2011-01-04, 37 fields added/edited/deleted
Complete Update on 03/05/2003, 1 field added/edited/deleted.
Field Update on 01/14/2002, 1 field added/edited/deleted.
Field Update on 08/08/2001, 1 field added/edited/deleted.
Complete Update on 03/28/2000, 1 field added/edited/deleted.
Complete Update on 02/02/2000, 1 field added/edited/deleted.
Complete Update on 09/21/1999, 1 field added/edited/deleted.
Complete Update on 08/26/1999, 1 field added/edited/deleted.
Complete Update on 06/03/1999, 1 field added/edited/deleted.
Complete Update on 06/02/1998, 1 field added/edited/deleted.
Complete Update on 10/17/1997, 1 field added/edited/deleted.
Complete Update on 03/11/1997, 2 fields added/edited/deleted.
Complete Update on 01/19/1996, 1 field added/edited/deleted.
Complete Update on 08/29/1995, 15 fields added/edited/deleted.
Field Update on 05/26/1995, 1 field added/edited/deleted.
Field Update on 12/21/1994, 1 field added/edited/deleted.
Complete Update on 03/25/1994, 1 field added/edited/deleted.
Complete Update on 02/05/1993, 1 field added/edited/deleted.
Field update on 12/12/1992, 1 field added/edited/deleted.
Complete Update on 12/14/1984
Created 19830315 by SYS
Warning:
Your baby’s health depends on carefully following these directions. Proper hygiene, handling and storage are important when preparing infant formula. Failure to follow these directions could result in severe harm. Ask your baby’s doctor if you need to use cooled, boiled water.

For Your Baby’s First Year

INGREDIENTS:
ORGANIC NONFAT MILK, SUGAR, MALTODEXTRIN, ORGANIC COCONUT OIL; ORGANIC M. ALPINA OIL†, BETA-CAROTENE, LUTEIN, LYCOPENE, FRUCTOOLIGOSACCHARIDES, POTASSIUM CITRATE, CALCIUM PHYTATE, SODIUM Diphosphate, ASCORBIC ACID, SOY LECITHIN, ASCORBYL PALMITATE, FERROUS SULFATE, SALT, CHOLINE CHLORIDE, SODIUM MALTOL, MIXED TOCOPHEROLS, METHYLcobALAMIN, CYCLOHEXYLMETHYLcobALAMIN, DEXTRIN, ALUMINUM HYDROXIDE, NIACINAMIDE, CALCIUM PANTOTHENATE, L-CARNITINE, VITAMIN A PALMITATE, VITAMIN D3, VITAMIN E, VITAMIN K, p-TOCOPHERYL ACETATE, Niacin, Vitamin B6, Folic Acid, Choline Chloride, Zinc Sulfate, Magnesium Chloride, Copper Sulfate, Iodine, Calcium Ascorbyl Glycoside, Manganese Sulfate, Selenium Yeast, Calcium Pantothenate, Vitamin A Palmitate, Vitamin D3, Vitamin B12, Lutein,lycopenes, fructooligosaccharides, potassium citrate, calcium phosphate, potassium hydroxide and nucleotides (cytidine 5’-monophosphate, disodium guanosine triphosphate, disodium guanosine monophosphate). The milk used in this product is heat treated to ensure quality and to assure the absence of certain bacteria. The milk is primarily of Jersey origin, and some other sources may be used.

†SOURCE OF ARACHIDONIC ACID (ARA)
*SOURCE OF DOCOSAHEXAENOIC ACID (DHA)

NET WT. 1.45 LB (658 g)

USE BY DATE MAY BE 12 MONTHS FROM DATE SHOWN AS DIRECTED. USE A NEW BOTTLE AND MIXING VESSEL WITH EACH FEEDING. STORE UNOPENED OR OPENED CONTAINER AT ROOM TEMPERATURE; AVOID EXTREME TEMPERATURES. FOR USE WITH INFANT FORMULA INSTRUCTIONS SIDE OF CONTAINER.

POLLUTION CONTROL: AVOID PLACING廢棄物於為奴役中的土地

The product of the land of the people of the earth.

APPENDIX B

Appendix B
Material Safety Data Sheet
Ascorbyl palmitate MSDS

Section 1: Chemical Product and Company Identification

Product Name: Ascorbyl palmitate
Catalog Codes: SLA2635, SLA4138
CAS#: 137-66-6
RTECS: CI7671040
TSCA: TSCA 8(b) inventory: Ascorbyl palmitate
CI#: Not available.

Synonym: L-Ascorbic Acid, 6-Hexadecanoate
Chemical Name: Ascorbyl Palmitate
Chemical Formula: C22H38O7

Contact Information:
Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396
US Sales: 1-800-901-7247
International Sales: 1-281-441-4400
Order Online: ScienceLab.com

CHEMTREC (24HR Emergency Telephone), call: 1-800-424-9300
International CHEMTREC, call: 1-703-527-3887
For non-emergency assistance, call: 1-281-441-4400

Section 2: Composition and Information on Ingredients

Composition:

<table>
<thead>
<tr>
<th>Name</th>
<th>CAS #</th>
<th>% by Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascorbyl palmitate</td>
<td>137-66-6</td>
<td>100</td>
</tr>
</tbody>
</table>

Toxicological Data on Ingredients: Ascorbyl palmitate: ORAL (LD50): Acute: 25000 mg/kg [Mouse]. DERMAL (LD50): Acute: &gt;3000 mg/kg [Guinea pig].

Section 3: Hazards Identification

Potential Acute Health Effects:
Hazardous in case of eye contact (irritant), of inhalation. Slightly hazardous in case of skin contact (irritant), of ingestion.

Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Not available. TERATOGENIC EFFECTS: Not available. DEVELOPMENTAL TOXICITY: Not available. Repeated or prolonged exposure is not known to aggravate medical condition.

Section 4: First Aid Measures

Eye Contact:
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Cold water may be used. WARM water MUST be used. Get medical attention.
**Skin Contact:** Wash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops.

**Serious Skin Contact:** Not available.

**Inhalation:**
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.

**Serious Inhalation:** Not available.

**Ingestion:**
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Loosen tight clothing such as a collar, tie, belt or waistband. Get medical attention if symptoms appear.

**Serious Ingestion:** Not available.

---

**Section 5: Fire and Explosion Data**

**Flammability of the Product:** May be combustible at high temperature.

**Auto-Ignition Temperature:** Not available.

**Flash Points:** CLOSED CUP: Higher than 93.3°C (200°F).

**Flammable Limits:** Not available.

**Products of Combustion:** These products are carbon oxides (CO, CO₂).

**Fire Hazards in Presence of Various Substances:** Slightly flammable to flammable in presence of heat.

**Explosion Hazards in Presence of Various Substances:**
Risks of explosion of the product in presence of mechanical impact: Not available. Risks of explosion of the product in presence of static discharge: Not available.

**Fire Fighting Media and Instructions:**
SMALL FIRE: Use DRY chemical powder. LARGE FIRE: Use water spray, fog or foam. Do not use water jet.

**Special Remarks on Fire Hazards:** Not available.

**Special Remarks on Explosion Hazards:** Not available.

---

**Section 6: Accidental Release Measures**

**Small Spill:**
Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by spreading water on the contaminated surface and dispose of according to local and regional authority requirements.

**Large Spill:**
Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water on the contaminated surface and allow to evacuate through the sanitary system.

---

**Section 7: Handling and Storage**

**Precautions:**
Keep away from heat. Keep away from sources of ignition. Empty containers pose a fire risk, evaporate the residue under a fume hood. Ground all equipment containing material. Do not ingest. Do not breathe dust. Avoid contact with eyes. Wear suitable protective clothing. In case of insufficient ventilation, wear suitable respiratory equipment. If ingested, seek medical advice immediately and show the container or the label.

**Storage:** Keep container tightly closed. Keep container in a cool, well-ventilated area.
**Section 8: Exposure Controls/Personal Protection**

**Engineering Controls:**
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants below the exposure limit.

**Personal Protection:** Safety glasses. Synthetic apron. Gloves (impervious).

**Personal Protection in Case of a Large Spill:**
Splash goggles. Full suit. Boots. Gloves. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling this product.

**Exposure Limits:** Not available.

---

**Section 9: Physical and Chemical Properties**

**Physical state and appearance:** Solid. (Powdered solid.)

**Odor:** Citrus-like

**Taste:** Not available.

**Molecular Weight:** 414.54 g/mole

**Color:** White to yellowish.

**pH (1% soln/water):** Not available.

**Boiling Point:** Not available.

**Melting Point:** 116°C (240.8°F)

**Critical Temperature:** Not available.

**Specific Gravity:** Not available.

**Vapor Pressure:** Not applicable.

**Vapor Density:** Not available.

**Volutility:** Not available.

**Odor Threshold:** Not available.

**Water/Oil Dist. Coeff.:** Not available.

**Ionicity (in Water):** Not available.

**Dispersion Properties:** Not available.

**Solubility:** Very slightly soluble in cold water.

---

**Section 10: Stability and Reactivity Data**

**Stability:** The product is stable.

**Instability Temperature:** Not available.

**Conditions of Instability:** Excess heat, incompatible materials

**Incompatibility with various substances:** Not available.

**Corrosivity:** Not available.

**Special Remarks on Reactivity:** Not available.
### Section 11: Toxicological Information

**Routes of Entry:** Inhalation. Ingestion.

**Toxicity to Animals:**
Acute oral toxicity (LD₅₀): 25000 mg/kg [Mouse]. Acute dermal toxicity (LD₅₀): >3000 mg/kg [Guinea pig].

**Chronic Effects on Humans:** Not available.

**Other Toxic Effects on Humans:**
Hazardous in case of inhalation. Slightly hazardous in case of skin contact (irritant), of ingestion.

**Special Remarks on Toxicity to Animals:** Not available.

**Special Remarks on Chronic Effects on Humans:** Not available.

**Special Remarks on other Toxic Effects on Humans:**
Acute Potential Health Effects: Skin: May cause skin irritation. Eyes: May cause eye irritation. Inhalation: May cause respiratory tract irritation. Ingestion: May cause gastrointestinal (digestive) tract irritation. May affect metabolism and urinary system. Chronic Potential Health Effects: no information found.

### Section 12: Ecological Information

**Ecotoxicity:** Not available.

**BOD₅ and COD:** Not available.

**Products of Biodegradation:**
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.

**Toxicity of the Products of Biodegradation:** The product itself and its products of degradation are not toxic.

**Special Remarks on the Products of Biodegradation:** Not available.

### Section 13: Disposal Considerations

**Waste Disposal:**
Waste must be disposed of in accordance with federal, state and local environmental control regulations.

### Section 14: Transport Information

**DOT Classification:** Not a DOT controlled material (United States).

**Identification:** Not applicable.

**Special Provisions for Transport:** Not applicable.

### Section 15: Other Regulatory Information

**Federal and State Regulations:** TSCA 8(b) inventory: Ascorbyl palmitate

**Other Regulations:** EINECS: This product is on the European Inventory of Existing Commercial Chemical Substances.

**Other Classifications:**
WHMIS (Canada): Not controlled under WHMIS (Canada).

DSCL (EEC):
R36- Irritating to eyes. S2- Keep out of the reach of children. S46- If swallowed, seek medical advice immediately and show this container or label.

HMIS (U.S.A.):
- Health Hazard: 2
- Fire Hazard: 1
- Reactivity: 0
- Personal Protection: C

National Fire Protection Association (U.S.A.):
- Health: 2
- Flammability: 1
- Reactivity: 0
- Specific hazard:

Protective Equipment:
Gloves (impervious). Synthetic apron. Not applicable. Safety glasses.

---

Section 16: Other Information

References: Not available.

Other Special Considerations: Not available.

Created: 10/09/2005 04:16 PM

Last Updated: 11/01/2010 12:00 PM

The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com has been advised of the possibility of such damages.
Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the Tolerable Upper Intake Level of Vitamin C (L-Ascorbic acid, its calcium, potassium and sodium salts and L-ascorbyl-6-palmitate) (Request No EFSA-Q-2003-018) (adopted on 28 April 2004)

SUMMARY

The European Food Safety Authority is asked to derive an upper level for the intake of vitamin C from food that is unlikely to pose a risk of adverse health effects.

Vitamin C is a water soluble vitamin that is an important anti-oxidant in the body. Insufficient intake results in the deficiency condition scurvy.

The vitamin is of low acute toxicity as indicated by the limited data available from studies in animals and humans. Despite the extensive use of high doses of vitamin C in some vitamin supplements, there have been few controlled studies that specifically investigated adverse effects. Overall, acute gastrointestinal intolerance (e.g., abdominal distension, flatulence, diarrhoea, transient colic) is the most clearly defined adverse effect at high intakes, but there are limited data on the dose-response relationship for adults or for groups such as children or the elderly. While there is uncertainty whether high intakes of vitamin C increase renal excretion of oxalate which could increase the risk of renal stones, an increased risk of kidney stones was not found in individuals with habitual intakes of 1.5 g/day. There are insufficient data to establish a tolerable upper intake level for vitamin C.

The available human data suggest that supplemental daily doses of vitamin C up to about 1 g, in addition to normal dietary intakes, are not associated with adverse gastrointestinal effects, but that acute gastrointestinal effects may occur at higher intakes (3–4 g/day). The absorption of vitamin C is saturated at high doses, and therefore intakes above 1 g/day would be associated with negligible increased uptake and tissue levels, but an increased risk of adverse gastrointestinal effects.

The average daily intakes reported in surveys in European countries are above the recommended daily intakes, with the 95th percentile intakes from food and supplements ranging up to about 1 g/day. These dietary intakes do not represent a cause for concern.

There has not been a systematic assessment of the safety of the long-term use of high dose vitamin C supplements.

KEY WORDS

Vitamin C, ascorbic acid, tolerable upper intake level, gastrointestinal effects, food safety.
BACKGROUND


In addition, and as announced in its White Paper on Food Safety, the Commission aims to put forward a proposal for harmonising legislation concerning the addition of vitamins and minerals to foods.

With a view to provide scientific support to the European Commission’s legislative work in this field, the Scientific Committee on Food (SCF) issued, from October 2000 to April 2003, a series of opinions on tolerable upper intake levels of individual vitamins and minerals and safety factors in relation to their use in fortified foods and food supplements (available on the Internet at: http://europa.eu.int/comm/food/fs/sc/scf/out80_en.html).

The SCF opinions covered 22 out of the 29 nutrients, which were considered to be within their mandate for this task. The SCF did not have sufficient time to adopt opinions for the following vitamins and minerals: vitamin C, chloride, fluoride, iron, phosphorus, potassium and sodium. In addition, during the decision making process for the adoption of Directive 2000/46/EC on food supplements the Parliament requested that boron, nickel, silicon, vanadium and tin should be allowed to be used in food supplements. Therefore, the European Food Safety Authority is asked to provide scientific opinions on the remaining 12 vitamins and minerals in accordance with the present terms of reference.

TERMS OF REFERENCE

With respect to the outstanding 12 vitamins and minerals, the European Food Safety Authority is asked 1) to review the upper levels of daily intakes that are unlikely to pose a risk of adverse health effects; 2) to provide the basis for the establishment of safety factors, where necessary, which would ensure the safety of fortified foods and food supplements containing the aforementioned nutrients.

ASSESSMENT

1. INTRODUCTION

Vitamin C (3-oxo-L-gulofuranolactone or L-threo-hex-2-enonic acid) is a 6-carbon hydroxylactone that is structurally related to glucose. It is a micronutrient essential to humans, primates and guinea pigs, but which is synthesised by other mammalian species from glucose and galactose. It is readily oxidised to L-dehydroascorbic acid, in which the unsaturated 2,3-dihydroxy group is replaced by a saturated 2,3-diketone function; L-dehydroascorbic acid can be reduced back to ascorbic acid.

Vitamin C is highly water soluble, and in solution can be oxidised by atmospheric oxygen to give an equilibrium mixture of ascorbic and dehydroascorbic acids. Vitamin C has important

anti-oxidant properties, and protects cells against oxidative stress. Because of this general cytotoxic role, its importance has been investigated in a variety of clinical conditions, including cancer, vascular disease, and cataracts.

Vitamin C deficiency in humans leads to clinical syndromes known as scurvy in adults and Moeller-Barlow disease in children (SCF, 1993), conditions which are associated with intakes of less than 10 mg/day. Early or prescorbutic symptoms in adults include fatigue, weakness, anaemia and aching joints and muscles, while there are important effects on bone tissue in children. Later stages of deficiency are characterised by capillary fragility causing bleeding from the gums and haemorrhages, and delayed wound healing due to impaired collagen synthesis.

Advice by Linus Pauling that daily intakes of 1 g or more of vitamin C can protect against the common cold (see Miller and Hayes, 1982) was followed by other claims of beneficial effects on a variety of conditions. Because of the media attention given to these claims and the apparently low toxicity of vitamin C there has been extensive human exposure to intakes up to 10 g/day (Miller and Hayes, 1982). However despite this extensive human exposure, there are only limited data that are appropriate for use in risk assessment.

Recent reviews of vitamin C by the Food and Nutrition Board in the USA (FNB, 2000) and the Expert Group on Vitamins and Minerals in the UK (EGVM, 2003) have recommended an upper level of 2 g/day and a guidance level of 1 g/day, as supplemental intake, respectively.

2. NUTRITIONAL BACKGROUND, FUNCTION, METABOLISM AND INTAKE

Major food sources of vitamin C are plants such as citrus fruits, soft fruits and green vegetables. Animal tissues also contain vitamin C, with kidney and liver representing good sources. The amounts of vitamin C present in the food when consumed may be reduced, because it is readily lost due to dissolution in water and oxidation during cooking processes such as boiling.

Ascorbic acid is a permitted anti-oxidant additive in food, with no specified limits on the level of use. Vitamin C is present in numerous dietary supplements with manufacturer recommended daily intakes of 60-3000 mg in single vitamin preparations and 10-1000 mg/day in multi-vitamin preparations (EGVM, 2003).

In 1992, the Scientific Committee for Food (SCF, 1993) recommended a Population Reference Intake of 45 mg/day for adults, with an increase to 55 mg/day in pregnancy, and to 70 mg/day during lactation.

Vitamin C has a number of biochemical roles in the body (Basu and Dickerson, 1996). It is a strong reducing agent and antioxidant, which is important in preventing the damaging effects of free radicals. Vitamin C is an enzyme co-factor for many biochemical reactions, especially those involving oxidations, such as the synthesis of hydroxyproline from proline for collagen biosynthesis, mono-oxygenases, dioxygenases and mixed function oxygenases. It is important in the synthesis and stabilisation of neurotransmitters and carnitine, and increases the gastrointestinal absorption of non-haem iron by reducing ferric to ferrous iron (SCF, 1993).
Gastrointestinal absorption of low doses of vitamin C is efficient, and occurs in the small intestine via a sodium-dependent active transport mechanism. The extent of absorption of vitamin C is 80-90% at the usual intakes from food of 30-180 mg/day (SCF, 1993), but because the transporter is saturable, absorption efficiency gradually decreases at higher intakes (Kallner et al., 1979 and 1985; Hornig and Moser, 1981; Blanchard et al., 1997). There is a non-linear relationship between daily intake of vitamin C and plasma concentrations, with a 5-fold increase in intake from 0.5 g/day to 2.5 g/day producing only a 20% increase in plasma levels (Levine et al., 1996 and 1999). Ascorbyl palmitate is probably hydrolysed in the lumen of the gastrointestinal tract prior to absorption, but data defining the in vivo fate of this synthetic form of vitamin C have not been identified.

Ascorbic acid is widely distributed in all tissues of the body, with higher levels found in the adrenal and pituitary glands and the retina, and lower levels in kidney and muscle tissue. Vitamin C can be detected in most tissues and exists as an equilibrium mixture of ascorbic acid and dehydroascorbic acid, dependent on the redox status of the cells. Plasma and urinary vitamin C are not reliable indicators of body stores of vitamin C because they are influenced by recent dietary intake. Leukocytes contain higher concentrations of vitamin C than plasma, blood or serum (Levine et al., 1996), and may provide a more reliable indicator of status. A vitamin C concentration in leukocytes below 0.01 mg per 10^8 cells is generally regarded as indicative of deficiency.

Vitamin C is readily oxidised to dehydroascorbic acid, which can be reduced back to ascorbic acid or hydrolysed to diketogulonic acid and then oxidised to oxalic and threonic acid, xylitol, xylonic acid and lyxonic acid (Basu and Dickerson, 1996). Some oxidation to carbon dioxide occurs at high doses, possibly due to metabolism of unabsorbed ascorbate by the intestinal microflora (Kallner et al., 1985). Ascorbic acid may also undergo limited conjugation with sulphate to form ascorbate-2-sulphate, which is excreted in urine. Unchanged ascorbic acid and its metabolites are excreted in the urine. Approximately 3% of a 60 mg oral dose is eliminated in the faeces. At intakes above 80-100 mg/day, most of the additional absorbed vitamin is excreted unchanged in the urine, indicating that tissue reserves are saturated at this intake level (SCF, 1993; FNB, 2000). This increasing renal elimination of ascorbic acid with increase in dose results in an inverse relationship between the elimination half-life and the dosage (Kallner et al., 1979) and probably arises from saturation of reabsorption from renal tubule (Blanchard et al., 1997).

The average daily intakes in European countries are above the reference intake established by the SCF in 1993, with relatively consistent data in different countries (Table 1). The 97.5th percentiles of intake are about 5-6 times the reference intake.

3. HAZARD IDENTIFICATION

3.1 Genotoxicity

The genetic toxicology of ascorbic acid was reviewed by Shamberger (1984) at which time there was evidence for indirect mutagenic effects via the generation of oxidative damage in the presence of transition metals, and also for anti-mutagenic effects in a variety of systems.

Vitamin C would be expected to be anti-mutagenic, because of its antioxidant properties, and there are data consistent with this. For example, ascorbic acid reduces the spontaneous...
mutation rate in mismatch repair-defective cells (Glaab et al., 2001), protects against gamma-ray induced damage (Konopacka and Rzeszowska-Wolny, 2001) and reduces the activity of some genotoxic compounds (Blasiak et al., 2001; Nefic, 2001; Rao et al., 2001; Kaya et al., 2002; Chang et al., 2002), including important food-borne mutagens such as patulin (Alves et al., 2000) and toxins such as zearalenone and ochratoxin A (Grosse et al., 1997 - based on a reduction in DNA adducts measured by $^{32}$P-post labelling).

Table 1. The daily intakes of vitamin C in EU countries (mg/day)

<table>
<thead>
<tr>
<th>Population</th>
<th>N</th>
<th>Method</th>
<th>Supplements</th>
<th>Mean</th>
<th>97.5%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td></td>
<td>men + women</td>
<td>2488</td>
<td>24 h recall</td>
<td>Not defined</td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td>men</td>
<td>854</td>
<td>7-day record</td>
<td>Not defined</td>
</tr>
<tr>
<td></td>
<td></td>
<td>women</td>
<td>1134</td>
<td></td>
<td>Not defined</td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td>men</td>
<td>1268</td>
<td></td>
<td>Computer-assisted</td>
</tr>
<tr>
<td></td>
<td></td>
<td>women</td>
<td>1540</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>men</td>
<td>240</td>
<td></td>
<td>dietary</td>
</tr>
<tr>
<td></td>
<td></td>
<td>women</td>
<td>347</td>
<td></td>
<td>interview</td>
</tr>
<tr>
<td>Italy</td>
<td></td>
<td>household</td>
<td>2734</td>
<td>7-day record</td>
<td>+</td>
</tr>
<tr>
<td>Ireland</td>
<td></td>
<td>men</td>
<td>662</td>
<td></td>
<td>7-day record</td>
</tr>
<tr>
<td></td>
<td></td>
<td>women</td>
<td>717</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>men</td>
<td>662</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>women</td>
<td>717</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Netherlands</td>
<td></td>
<td>household</td>
<td>5958</td>
<td>2-day record</td>
<td>-</td>
</tr>
<tr>
<td>Sweden</td>
<td></td>
<td>men</td>
<td>1897</td>
<td></td>
<td>8-day record</td>
</tr>
<tr>
<td></td>
<td></td>
<td>women</td>
<td>2223</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>men</td>
<td>770</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>women</td>
<td>1655</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UK</td>
<td></td>
<td>men</td>
<td>833</td>
<td></td>
<td>7-day record</td>
</tr>
<tr>
<td></td>
<td></td>
<td>women</td>
<td>891</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>men</td>
<td>833</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>women</td>
<td>891</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Although ascorbic acid is an antioxidant via its conversion to dehydroascorbic acid, the reversibility of the reaction can lead to the generation of reactive oxygen species via redox cycling (Ballin et al., 1988; Stadtman, 1991). This may be involved in some positive genotoxic effects reported with vitamin C in vitro, such as single strand breaks produced by sodium ascorbate (Singh, 1997), weak sister chromatid exchange (SCE) activity (Galloway and Painter, 1979; Speit et al., 1980; Best and McKenzie, 1988) and activity in the comet assay (Blasiak et al., 2000). Ascorbic acid has been reported to increase the genotoxicity of mitomycin C (Krishnaja and Sharma, 2003), cadmium chloride (Blasiak et al., 2000) and cobalt chloride (Kaya et al., 2002). The results obtained may depend on the concentrations of
vitamin C studied, with protective activity at low concentrations but cytotoxicity and an increase in genotoxic activity at concentrations more than 200 µg/mL (Antunes and Takahashi, 1999). Oral and intraperitoneal doses of up to 10 g/kg in hamsters did not induce SCEs (Speit et al., 1980).

Positive genotoxicity results tended to occur in vitro when vitamin C was tested in the presence of metal ions such as iron and copper, which may be related to its reduction of the metal followed by the formation of highly reactive hydroxyl radicals via a Fenton reaction (Carr and Frei, 1999). However, DNA-reactive species can be generated by interaction between vitamin C and lipid hydroperoxide decomposition in the absence of transition metal ions (Lee et al., 2001); the in vitro concentrations used in this study were similar to those present in plasma after doses of 200 mg/day, but the toxicological significance of this observation is unclear.

Podmore et al. (1998a) reported that the administration of 500 mg/day of vitamin C supplements to 28 human volunteers for 6 weeks caused an increase in 8-oxoadenine but a decrease in 8-oxoguanine in the DNA of isolated lymphocytes measured by gas chromatography-mass spectrometry (GC-MS), possibly due to its pro-oxidant effect. Two letters were published as a consequence of this report, which pointed out that the dosage given would not have increased the intracellular concentrations of ascorbate in lymphocytes, and that the increased oxidation could be an artefact formed by monocytes in the lymphocyte preparation (Levine et al., 1998), that artefacts were not adequately excluded, the study was not a randomised double-blind placebo controlled investigation, and the authors did not give information about smoking habits or cite previous publications (Poulsen et al., 1998). In their reply to these letters, Podmore et al. (1998b) provided further support for the validity of their findings and pointed out that because 8-oxoadenine is 10-times less mutagenic than 8-oxoguanine, their results are consistent with an “overall profound protective effect”.

An increase in total damage to lymphocyte DNA bases (but not in 8-hydroxyadenine or 8-hydroxyguanine) was reported in a study in which one group of 20 volunteers who were given 14 mg iron plus either 60 or 260 mg of vitamin C, but not in a second group of 18 subjects who were treated in the same way but had slightly lower pre-treatment plasma levels of ascorbic acid (Rehman et al., 1998). In a subsequent paper by the same research group, treatment of 20 healthy adults with ascorbate (280 mg/day), with or without supplemental iron (14 mg/day), for periods of 6 weeks in a cross-over design showed no significant rise in oxidative DNA damage as measured by GC-MS (Proteggente et al., 2000): significant decreases in 8-oxo-7,8-dihydroguanaine and 5-hydroxymethyl uracil were found during treatment with ascorbate and the authors concluded that there was no compelling evidence of a pro-oxidant effect resulting in DNA damage. In vivo administration of 1g vitamin C daily for 42 days to human volunteers did not influence the extent of endogenous DNA damage in peripheral lymphocytes measured using an Elisa technique, but reduced the extent of ex vivo peroxide-induced damage (Brennan et al., 2000). The significance of these observations is unclear and currently under further study.

Overall, the data currently available do not allow an adequate evaluation of the genotoxic potential of high intakes of vitamin C, and in particular its capacity to induce gene and chromosomal mutations. The significance of oxidative DNA damage observed in vitro or in vivo at high concentrations is unclear.
3.2 Animal toxicity data

Vitamin C has low acute toxicity. High doses of vitamin C (100 mg per 160 g animal per day) are associated with decreased growth rates in guinea pigs fed a nutritionally inadequate diet of unfortified wheat flour, but weight gain was not altered if the treated animals were fed a wheat flour diet fortified with casein (Nandi et al., 1973). No effects on reproductive or developmental parameters were found in guinea pigs, rats and hamsters given oral doses of up to 400 mg/kg body weight/day during pregnancy (Alleva et al., 1976) or in rats and mice given up to 1000 mg/kg body weight/day (Frohberg et al., 1973). A conditioned increase in vitamin C requirements has been reported in guinea pigs (Sorensen et al., 1974).

There have been a number of studies in which rats have been given high dietary concentrations of the sodium salt of ascorbic acid and the free acid in relation to the role of sodium ions in the generation of bladder hyperplasia and cancer in male rats. Using a 2-stage model of bladder carcinogenesis, in which male rats were treated with possible promoters of bladder carcinogenesis for 6 weeks, Cohen et al. (1991) showed that sodium ascorbate at 5% in the diet (equivalent to about 2500 mg/kg body weight/day) increased the incidence of bladder cancers, but that an equimolar dietary concentration of ascorbic acid (4.44%) was inactive. In a subsequent study in which sodium ascorbate was given in the diet to rats without pre-treatment with a carcinogen, significant increases in simple, papillary and nodular hyperplasia in the urinary bladder were detected in rats fed diets containing 5% or 7% sodium ascorbate, but these effects were abolished by co-treatment with ammonium chloride which acidified the urine (Cohen et al., 1998); there was a small and non-significant increase in the numbers of papillomas and carcinomas in the urinary bladder at dietary levels of 5% (n=1) and 7% (n=2) compared to control (n=0) or 1% dietary level (n=0). In 1993, the JECFA concluded that similar effects produced by the sodium salt of saccharin were related to sodium-induced changes in urine volume, osmolality and pH, and were not relevant to human health (JECFA, 1993).

Dietary administration of ascorbyl palmitate at levels of 2000 ppm and 4000 ppm (equivalent to daily intakes of about 100 and 200 mg/kg body weight per day) to male rats treated with the colon carcinogen azoxymethane caused a significant reduction in the incidence (% of animals with tumours) and the multiplicities of invasive and total adenocarcinomas of the colon (Rao et al., 1995). In contrast, administration of 2% ascorbyl palmitate in the diet of mice (equivalent to daily intakes of about 2000 mg/kg body weight per day) did not attenuate the hyperplastic and dysplastic effects of azoxymethanol in the colon (Huang et al., 1992).

3.3 Human data

Despite a number of clinical studies in which high doses of vitamin C (up to 1 g or more per day) have been given, there is a limited database on tolerability or adverse effects. A number of studies with different doses and durations have not reported adverse effects, but it is difficult to determine the significance of these because it is frequently unclear how any adverse effects were investigated (reviewed in Carr and Frei, 1999) (EGVM, 2003). In addition many studies have used a combination of vitamins and minerals, and identifying any effect of vitamin C per se is not possible because other parts of the treatment could mask adverse effects.

Adverse effects were not reported in recent studies in which 12 healthy adult volunteers received 500 mg/day for 8 weeks (McArdle et al., 2002), 19 patients with hypertension...
received 500 mg/day for 30 days (Duffy et al., 1999), 28 male smokers received 500 mg/day for 4 weeks (Aghdassi et al., 1999), 18 healthy male adults given 2 g/day for 6 weeks (Tofler et al., 2000), 130 healthy adults given 250 mg of slow release vitamin C for 3 years (Salonen et al., 2000), 8 adults received increasing daily doses up to a maximum of 2 g/day for 2 weeks (Johnston and Cox., 2001), 5 adults received 1 g/day for 6 months (Pullin et al., 2002) and 30 adults given daily doses of 500 mg for 6 weeks (Hamilton et al., 2000). Most of these studies had primary endpoints related to a health benefit, and assessment of adverse effects or tolerability was not a part of the study design.

A double-blind, cross-over study on the effects of daily doses of 3 g of vitamin C, combined with very high doses of nicotinamide (3 g), calcium pantothenate (1.2 g) and pyridoxine (0.6 g), in 41 children with attention deficit disorders (Haslam et al., 1984) reported an increase in serum transaminases. However, this cannot be assigned to the vitamin C component, because of the complex megavitamin regimen. There was little information reported on general tolerability, but 3 children did not complete the study because of excessive vomiting, abdominal discomfort or an inability to swallow the vitamin capsules and “some patients experienced nausea and vomiting during the course of treatment”.

Vitamin C was administered to 10, 269 adults aged 40-80 with coronary disease at a daily dose of 250 mg/day (in combination with 600 mg vitamin E and 20 mg β-carotene) for up to 5 years. The subjects showed good compliance and there were no significant differences in mortality or morbidity compared with a placebo group of equal size (Heart Protection Study, 2002). No effects on inflammatory markers were reported in a recent long-term multi-vitamin study (Bruunsgaard et al., 2003) in which 52 men aged 47-70 were treated for 3 years with a combination of 500 mg vitamin C and 182 mg of α-tocopherol daily, but it is unclear to what extent other effects, such as gastrointestinal problems, would have been recorded.

A retrospective cohort study of 994 women, of whom 277 were regular users of vitamin C supplements for up to 12 years, reported a significant increase in bone mineral density of the neck of the femur; no side effects were reported but no parameters other than bone mineral density were assessed (Morton et al., 2001).

Adverse effect data were not reported in a 4-year double-blind, placebo-controlled study in which patients with a history of adenoma of the large bowel were given vitamin C (1 g/day) with either vitamin E (205 patients) or vitamin E plus β-carotene (175 patients) (Greenberg et al., 1994). Adherence to the prescribed regimen, and information about symptoms, illnesses and hospitalisations were assessed every 6 months. The numbers of patients who withdrew from the study were similar in all groups, but 4 subjects in the two vitamin C treatment groups “stopped taking the medications because of their presumed toxicity”; no other information was provided and tolerability during the study was not reported.

No subjective side effects were reported in the study of Cook et al. (1984) in which 17 adults were given 2 g/day with meals for 16 weeks.

No adverse effects were reported in a randomised, double-blind, placebo-controlled study in which 21 patients with coronary artery disease were given a single dose of 2 g vitamin C followed by 500 mg/day for 30 days (Gokce et al., 1999).
3.3.1. Gastrointestinal effects

Gastrointestinal effects are the most common adverse clinical events associated with acute, high doses of vitamin C (above 1 g daily), but these can be reduced by taking the vitamin after meals (reviewed in Miller and Hayes, 1982). The incidences of stomach pains, nausea and diarrhoea in children given 1 g/day for 3 months were similar to those in the control groups (Ludvigsson et al., 1977). Abdominal distension, flatulence, diarrhoea and transient colic were reported as “fairly frequent” in a study in healthy human volunteers given daily doses which increased by 1000 mg per day each week, with adverse effects reported at doses of 3-4 g/day, although no details were given of the exact dosing regimen or the numbers of subjects studied or their age, sex or body weight (Cameron and Campbell, 1974). Two out of 15 volunteers experienced diarrhoea when consuming 10 g of vitamin C daily for 5 days in a clinical study on oxalate excretion, despite the fact that the subjects were advised to take the vitamin C tablets at mealtimes to minimise the potential for adverse gastrointestinal effects (Wandzilak et al., 1994).

3.3.2 Renal effects

Adverse effects related to the renal system have been reported, including renal stones, renal tubular disease and oxaluria. Vitamin C consumption has been suggested to increase oxalate excretion and the risk of urinary stone formation, but the available data are both confusing and contradictory. An early report stated that there could be wide inter-subject differences in the excretion of oxalate following high doses of vitamin C (Briggs, 1976). An additional problem is that urinary oxalate can be produced from urinary ascorbic acid as an artefact of the analytical procedure, so that the validity of the analytical data depends on the extent to which this was controlled by the use of preservatives. Increased oxalate excretion would represent a risk factor for the formation of bladder stones, and there have been anecdotal case reports of kidney stones or other nephropathy (Nakamoto et al., 1998) in patients who have taken high daily doses of vitamin C.

Groups of 3 patients who had unilateral nephrostomy tubes after lithotripsy for renal stones were given supplemental doses of 100, 500, 1000, or 2000 mg ascorbic acid on days 2 and 3 postoperatively (Urvietzky et al., 1992). Urine specimens were collected from the nephrostomy catheter and also from the contralateral kidney directly into EDTA and sodium thimerosal preservative to stabilise ascorbic acid and oxalate; oxalate was measured following the removal of ascorbic acid with sodium nitrite. There was a statistically significant increase in urinary oxalate at doses of 1000 and 2000 mg. The authors estimated that there was a 6-13 mg/day increase in urinary oxalate excretion per 1000 mg/day ascorbic acid intake, and concluded that there was an increased risk of calcium oxalate renal stones.

Urinary excretion of oxalate was measured in 15 volunteers given ascorbic acid supplementation (1, 5 and 10 g/day for 5 days in a cross-over design) (Wandzilak et al., 1994). The 24-hour urine samples were preserved by reducing the pH to 2 by adding 20 mL of concentrated hydrochloric acid. Ascorbate was reported to be converted non-enzymatically into oxalate during analytical measurement. The study did not find an increase in urinary oxalate excretion after ex vivo non-enzymatic conversion of ascorbate to oxalate had been taken into account.

Supplemental vitamin C intakes of 1 g/day in 7 volunteers caused statistically significant increases in urinary excretion of oxalate (determined by an enzymatic method reported to be
free from interference by ascorbic acid) (Levine et al., 1996). An increase in urinary oxalate excretion, measured by an enzymatic assay on urine collections stabilised with acid, was also reported in 6 subjects given 1 g of supplemental ascorbate with 2.85 litres of orange juice containing 0.62 g of ascorbate daily for 4 days, but not in the same subject given 2 g of ascorbate per day for 4 days (Liebman et al., 1997).

Auer et al. (1998a) investigated the urinary excretion of oxalate in the presence and absence of EDTA preservation of the urine samples in 10 healthy male volunteers (with no history of stone formation) given 4 g of vitamin C daily for 5 days. Erroneously high oxalate concentrations were found in the absence, but not in the presence of EDTA. There was no significant increase in oxalate excretion at any stage of the protocol in EDTA preserved samples and it was concluded that large doses of vitamin C did not affect the principal risk factors associated with calcium oxalate kidney stone formation. In contrast, the same authors (Auer et al., 1998b) reported increased excretion of oxalate in EDTA treated urine samples from a single volunteer who took 8 g daily for a period of 8 days, at which time the study was terminated because of the detection of haematuria, which was associated with crystalluria.

A prospective study on the relationship between vitamin C intake and the risk of symptomatic kidney stones in a group of 45,251 men (Curhan et al., 1996) found no association with vitamin C intake in 751 cases of kidney stones. The age-adjusted relative risk for subjects with intakes of 1.5 g/day or more compared with less than 0.25g/day was 0.78 (95% confidence intervals 0.54-1.11), indicating that even if such doses do increase oxalate excretion, it is not a clinically significant effect. A similar study in a cohort of 85,557 women in whom there were 1078 incidences of kidney stones showed a relative risk of 1.06 (95% confidence intervals 0.69-1.64) for subjects with intakes of 1.5 g/day or more compared with less than 0.25 g/day (Curhan et al., 1999).

No significant relationships were found in an analysis of data from 5214 men and 5785 women between serum vitamin C concentrations and the prevalence of kidney stones, serum vitamin B₁₂ levels, or serum ferritin levels in men, but a negative correlation with serum ferritin was found for women (Simon and Hudes, 1999).

Increased excretion of uric acid has also been reported after the ingestion of 4 g or 8 g of ascorbic acid (Stein et al., 1976); although the available data at lower doses are limited and conflicting, in all studies hyperuricosuria was absent at doses of less than 1 g (Levine et al., 1999).

3.3.3 Other effects

Other anecdotally reported adverse effects include metabolic acidosis and changes in prothrombin activity, but a double-blind trial in patients given 200 mg/day showed no significant effect on the incidence of thrombotic episodes (Hornig and Moser, 1981).

A low incidence of adverse effects was reported during a study in patients with multiple sclerosis who were randomised to receive either supplements providing 2 g/day vitamin C, together with 6 mg/day sodium selenite and 480 mg/day vitamin E, or placebo for 5 weeks. The patients were interviewed about side effects after 2 weeks and 4 weeks of treatment. One out of the 10 patients receiving the active supplement reported slight facial erythema at week 2, which subsequently subsided during continued treatment, one reported a peculiar urine smell and another reported an increased number of headaches; three of the 10 patients
receiving the placebo reported an increased number of headaches (Mai et al., 1990). It cannot be determined from the data whether these were caused by the high doses of vitamin C or by the other constituents.

There is a suggestion in the literature of conditioned need-scurvy, in which scurvy-like symptoms occur soon after cessation of ingestion of high amounts of vitamin C (1 g or more per day) (Siegel et al., 1982). High intakes during pregnancy may result in neonatal scurvy by conditioning the offspring to require greater than the expected or recommended daily intakes, but the evidence for this is very limited (Cochrane, 1965). The reports of conditioned scurvy in humans are anecdotal and it does not represent a significant risk (Hornig and Moser, 1981).

Vitamin C increases iron uptake considerably from the gut when given to humans in single-meal studies in amounts from 25 to 1000 mg (Hallberg, 1985; Cook and Monsen, 1977). Studies of longer duration show a less marked effect (Hunt and Roughhead, 2000), but even a small increase could be important in subjects with conditions such as haemochromatosis (Gerster, 1999) or in subjects heterozygous for this condition. A dose of 2 g/day vitamin C taken with meals for 16 weeks in 17 healthy volunteers, and up to 24 months in 9 subjects, had no significant effect on body iron stores (Cook et al., 1984); this study was limited by the small numbers of participants and their variable iron status.

Large amounts of vitamin C were reported to destroy the vitamin B₁₂ content of food (Herbert and Jacob, 1974), and reduced vitamin B₁₂ levels in serum were reported in 3 out of 90 individuals consuming more than 1000 mg/day of vitamin C over a minimum of 3 years (Hind, 1975). However, subsequent reports showed that these observations arose from inadequate assay methods (Newmark et al., 1976 and 1979), and that ascorbic acid in blood can interfere with the measurement of vitamin B₁₂ (Herbert et al., 1978).

An increase in serum cholesterol was reported in 25 patients with atherosclerosis following treatment with 1 g vitamin C daily for 6 weeks, but not in healthy volunteers (Spittle, 1971); the authors suggested that this may have arisen due to mobilisation of arterial cholesterol deposits (which would be a benefit), but there was no direct evidence to support this. In contrast, a 10% decrease in total plasma cholesterol levels, but with no change in the cholesterol/HDL ratio, was reported in 18 healthy adult males given 2 g vitamin C daily for 6 weeks (Tofler et al., 2000).

There is conflicting evidence about the relationship between vitamin C intake and breast cancer. A prospective study in a large cohort (n=62,573) of postmenopausal women had found a lower risk of breast cancer in women with the highest intakes of vitamin C from food, but not from supplements (Verhoeven et al., 1997). However a recent nested case-control study found an increased risk of breast cancer among a cohort of postmenopausal Danish women (Nissen et al., 2003). A significantly increased risk was observed at intakes above 300 mg/day in comparison with intakes 60-150 mg/day. The numbers of cases and controls in the high-intake comparison were 62 and 41, respectively. When women who were taking supplemental vitamin C were excluded, the association between increasing vitamin C intake and breast cancer was weaker and no longer statistically significant.

In conclusion, the effects of vitamin C on cholesterol levels, conditioned need due to high intake, iron absorption, prothrombin time and vitamin B₁₂ degradation, breast cancer and the possible pro-oxidant activity of vitamin C are not sufficiently well documented or substantiated to be used as the basis for risk assessment. There have been conflicting reports
on the influence of vitamin C supplements on the presence of oxidised bases in DNA (Podmore et al., 1998; Rehman et al., 1998; Proteggente et al., 2000). These have been performed at relatively low doses (280 mg/day, 60 or 260 mg/day and 500 mg/day for 6 weeks respectively), and there are no data currently available at higher intakes.

4. DOSE-RESPONSE ASSESSMENT

Adequate data defining the dose-response relationships for each adverse effect described above are not available, because many studies used a single dose level only. Despite the extensive use of vitamin C supplements (up to 10 g/day) for the prevention of colds and other conditions, the tolerability of such intakes has not been subject to systematic assessment. Therefore there are few data to support the widely held view that high intakes of vitamin C are safe.

There have been a small number of studies that have investigated dose-response relationships in a controlled and scientific manner.

4.1 Gastrointestinal effects

Two out of 15 volunteers experienced diarrhoea when consuming 10 g of vitamin C daily for 5 days (Wandzilak et al., 1994). In a study in healthy human volunteers given increasing doses of vitamin C, abdominal distension, flatulence, diarrhoea and transient colic were reported as “fairly frequent” at doses of 3-4 g daily (Cameron and Campbell, 1974). Lower intakes appear to be tolerated without gastrointestinal effects since no subjective side effects were reported in 17 adults given 2 g/day for 16 weeks (Cook et al., 1984). The Miller and Hayes (1982) review concluded that doses greater than 1 g/day could result in adverse gastrointestinal effects. The data of Ludvigsson et al. (1977) indicate that 1 g/day would not produce adverse gastrointestinal effects in children.

4.2 Renal effects

A review of the early investigational studies on the relationship between ascorbic acid intake and oxalate excretion (Hornig and Moser, 1981) concluded that there were methodological problems with many of the studies.

A statistically significant increase in urinary oxalate excretion was reported in groups of 3 patients with calcium oxalate renal stones given 1 g or 2 g of supplemental ascorbic acid daily. Precautions were taken to prevent artefactual formation of oxalic acid by collection of intrarenal urine specimens from a catheter into EDTA and sodium thimerosol preservative (Urivetzky et al., 1992).

The more extensive cross-over study by Wandzilak et al. (1994) in which 15 subjects were given 1000, 5000 and 10,000 mg vitamin C each for 5 days reported no increase in oxalate excretion after correction for non-enzymatic ex vivo formation. However the data are difficult to interpret because of the highly acidic preservative used.

The two studies by Auer et al. (1998a and b) indicate no increase in the urinary excretion of oxalate in 10 healthy male volunteers (with no history of stone formation) given 4 g of
vitamin C daily for 5 days, but a marked increase associated with haematuria and crystalluria in a single individual who took 8 g daily for a period of 8 days.

In summary, one study reported that high intakes of vitamin C (1 or 2 g per day) increased the urinary excretion of oxalic acid in patients with renal stones, but this was not found in studies in healthy volunteers. Data from the cohort studies (Curhan et al., 1996 and 1999) show that intakes of 1.5 g/day do not increase the risk of kidney stone formation.

CONCLUSIONS AND RECOMMENDATIONS

1. DERIVATION OF A TOLERABLE UPPER INTAKE LEVEL (UL)

The vitamin is of low acute toxicity as indicated by the limited data available from studies in animals and humans. Despite the extensive use of high doses of vitamin C in some vitamin supplements, there have been few controlled studies that specifically investigated adverse effects. Based on the limited data, acute gastrointestinal intolerance is the most clearly defined adverse effect at high intakes, but there are limited data on the dose-response relationship for adults or for groups such as children or the elderly. There are insufficient data to establish a tolerable upper intake level for vitamin C.

2. RISK CHARACTERISATION

The available human data suggest that supplemental daily doses of vitamin C up to about 1 g in addition to normal dietary intakes are not associated with adverse gastrointestinal effects, but that acute gastrointestinal effects may occur at higher intakes (3-4 g/day). While there is uncertainty whether high intakes of vitamin C increase renal excretion of oxalate, which could increase the risk of renal stones, an increased risk of kidney stones was not found in individuals with habitual intakes of 1.5 g/day. The absorption of vitamin C is saturated at high doses, and therefore intakes above 1 g/day would be associated with negligible increased uptake and tissue levels, but an increased risk of adverse gastrointestinal effects. There are no data on the gastrointestinal absorption or tolerability of esterified forms of vitamin C, such as ascorbyl palmitate, but such esters might be expected to show similar properties, and therefore this conclusion applies to these forms as well as ascorbic acid and its salts.

The average daily intakes reported in surveys in European countries (Table 1) are above the Population Reference Intake, with the 95th percentile intake from food and supplements ranging up to about 1 g/day. These dietary intakes do not represent a cause for concern.

There has not been a systematic assessment of the safety of the long-term use of high dose vitamin C supplements.

3. RECOMMENDATIONS FOR FURTHER WORK

Any future studies on possible benefits of high intakes of vitamin C should investigate the nature and incidence of adverse effects. Very few data are available on esterified forms of vitamin C, such as ascorbyl palmitate, and these forms should be included in future studies.
The potential for vitamin C to induce gene or chromosomal mutations in vivo in humans at high doses (1 g or more) should be investigated especially pro-oxidant effects on DNA bases, using sensitive methods, because there are inadequate data to ensure the safety of long-term high-dose intakes.

Subgroups of the population at increased risk have not been investigated; individuals who are predisposed to gastrointestinal problems, kidney stones or who are unable to regulate iron absorption, due to haemochromatosis or thalassaemia, should be included in future studies on the possible beneficial and adverse effects of vitamin C.

The conflicting evidence about vitamin C intake and breast cancer is noted and no conclusion is possible at this time. The possible association warrants further research to clarify any relationship for both dietary sources and vitamin C supplements.

REFERENCES


Salonen JT, Nyyssonen K, Salonen R, Lakka HM, Kaikkonen J, Porkkala-Sarataho E,


PANEL MEMBERS


ACKNOWLEDGEMENT

The Scientific Panel on Dietetic Products, Nutrition and Allergies wishes to thank Jan Alexander, Angelo Carere, Werner Grunow, Andrew Renwick and Gerrit Speijers for their contributions to the draft opinion.